

Weekly

June 8, 2007 / Vol. 56 / No. 22

Decline in Breast Cancer Incidence — United States, 1999–2003

Breast cancer is the most commonly diagnosed cancer among females in the United States (1). The 2006 Annual Report to the Nation on the Status of Cancer (2) described a stabilization in female breast cancer incidence rates during 2001-2003, ending increases that began in the 1980s, and a decline in the number of breast cancer cases diagnosed in 2003. In addition, researchers who used 1990-2003 data from the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program, representing approximately 14% of the U.S. population, reported a 7% decrease in invasive breast cancer rates from 2002 to 2003 (3). To further assess breast cancer annual incidence rates during 1999-2003, CDC analyzed data collected by CDC's National Program of Cancer Registries (NPCR) and the NCI SEER program. These combined data account for approximately 86% of the U.S. population (1). The results of this analysis indicated that age-adjusted incidence rates for invasive breast cancer decreased each year during 1999-2003, with the greatest decrease (6.1%) occurring from 2002 to 2003; women aged \geq 50 years experienced a significant decrease during this period. Rates of in situ (i.e., noninvasive) breast cancer increased each year during 1999–2002 and then decreased from 2002 to 2003; women aged 50-79 years experienced a significant decrease during this period. Future studies should focus on determining potential causes for these decreases.

The most recent data available from population-based cancer registries affiliated with NPCR or the SEER program were used in this analysis; new cases of cancer were those reported to CDC (NPCR) as of January 31, 2006, or NCI (SEER) as of November 1, 2005*; data from four statewide NPCR/SEER registries are indicated as reported to CDC as of January 31, 2006. Data were evaluated according to United States Cancer Statistics eligibility criteria,[†] which require \geq 90% case ascertainment and an unduplication procedure within each registry to ensure that each cancer case is counted only once. Thirty-six NPCR and five SEER statewide registries met these criteria, representing 86.4% of the U.S. population for the years 1999-2003 (1). Because of the 86.4% population coverage, cancer rates derived from these data are considered to approximate actual incidence rates. A total of 1,043,480 diagnosed cases of breast cancer (in situ and invasive) among females were reported by these registries for the years 1999 to 2003 and used in this analysis. Annual incidence rates with confidence intervals were calculated. In situ and invasive breast cancer incidence rates were categorized by age at diagnosis; invasive cancer incidence rates were categorized by stage at diagnosis, race/ethnicity, and state of residence at diagnosis. Invasive breast cancer cases diagnosed during 1999-2000 were staged as localized, regional, or distant[§] using the 1977 SEER summary staging system, and cases diagnosed during 2001-2003 were staged using the newer 2000 SEER summary staging system (2). Incidence rates, per 100,000 females, are age adjusted to the 2000 U.S. standard population. Population estimates used as denominators in the rate calculations are

INSIDE

- 553 Hazardous Substances Released During Rail Transit 18 States, 2002–2007
- 556 West Nile Virus Activity United States, 2006
- 559 Notice to Readers

^{*} Medical records are the primary source of cancer incidence data. Staff members at health-care facilities abstract cancer incidence data from patients' medical records, enter the data into the facility's own cancer registry, if it has one, and then send the data to the regional or state registry. Both NPCR and SEER registries collect data using uniform data items and codes as documented by the North American Association of Central Cancer Registries. Additional information on NPCR and SEER methodology is available at http://www.cdc. gov/cancer/npcr/npcrpdfs/uscs_2003_technical_notes.pdf.

[†]Available at http://wonder.cdc.gov/wonder/help/cancer/uscs_2002_registry_ eligibility_criteria.html.

[§]Localized: cancer that is confined to the primary site. Regional: cancer that has spread directly beyond the primary site or to regional lymph nodes. Distant: cancer that has spread to other organs.

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2007;56:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH *Director* Tanja Popovic, MD, PhD

Chief Science Officer James W. Stephens, PhD (Acting) Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing B. Kathleen Skipper, MA (Acting) Director, Division of Health Information Dissemination (Proposed)

Editorial and Production Staff

Frederic E. Shaw, MD, JD Editor, MMWR Series Myron G. Schultz, DVM, MD (Acting) Deputy Editor, MMWR Series Suzanne M. Hewitt, MPA Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors Beverly J. Holland Lead Visual Information Specialist Lynda G. Cupell Malbea A. LaPete Visual Information Specialists Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

from the U.S. Census Bureau and modified by SEER to increase the accuracy of rates for the Hawaiian population (1). Statistically significant differences in rates between the years 2002 and 2003 were determined by using the rate ratio test in SEER*Stat (http://seer.cancer.gov/seerstat/index.html).

Age-adjusted annual incidence rates for invasive breast cancer decreased each year from 1999 to 2003, with the greatest decrease in rates occurring from 2002 to 2003 (Table). The rate from 2002 to 2003 decreased 6.1%, with a significant decrease occurring for all women aged \geq 50 years. The largest decrease (9.1%) occurred among women aged 60–69 years. For in situ cancers, rates increased each year from 1999 to 2002 and then decreased from 2002 to 2003, although the percentage decrease (2.7%) was smaller than that for invasive cancers (6.1%). Women aged 50–79 years experienced a significant decrease in incidence rates of in situ breast cancer from 2002 to 2003.

Whites had the highest incidence rates of invasive female breast cancer among racial/ethnic populations during 1999–2003, and American Indians/Alaska Natives (AI/ANs) had the lowest rates (Figure 1). From 2002 to 2003, all racial/ethnic groups other than AI/ANs experienced a significant decrease in incidence rates (blacks, 2.7%; Hispanics, 5.8%; Asians/Pacific Islanders [A/PIs], 6.1%; and whites, 6.4%) (Figure 1).

Rates of invasive breast cancer by stage at diagnosis declined during 1999–2003, with the largest decline (6.9%) (excluding unstaged cancer) occurring for localized cancer diagnosed from 2002 to 2003 (Table). Incidence rates of localized, regional, and unstaged female breast cancer decreased from 2002 to 2003; no significant change occurred in incidence rates of distant female breast cancer from 2002 to 2003.

Twenty-four of the 41 states included in this analysis experienced a significant decrease in incidence rates from 2002 to 2003 (range: 3.5% in Pennsylvania to 12.1% in Indiana) (Figure 2). Rates decreased by $\geq 6\%$ in 17 states, and no significant change occurred in 17 states. No significant increase occurred in any state included in the analysis, and no geographic pattern was observed.

Reported by: *SL Stewart, PhD, SA Sabatino, MD, SL Foster, MPH, LC Richardson, MD, Div of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC.*

Editorial Note: The findings in this report suggest that invasive female breast cancer rates have been decreasing in recent years, with a sharper decline occurring from 2002 to 2003. Furthermore, both in situ and invasive female breast cancer rates decreased from 2002 to 2003 across several age and stage groups and across most racial/ethnic populations. Decreases in 2003 occurred primarily among women aged \geq 50 years, a finding consistent with those of other studies (*3*). The overall decrease from 2002 to 2003 occurred in 24 states.

TABLE. Incidence rates* for in situ female breast cancer, by age group at diagnosis, and invasive female breast cancer, by age group and stage at diagnosis — United States,[†] 1999–2003

		1999		2000		2001		2002		2003	2002 to 2003
Breast cancer type	Rate	(95% CI§)	Rate	(95% CI)	% change						
In situ	28.0	(27.7–28.3)	28.6	(28.3–28.9)	29.2	(28.9–29.5)	29.3	(29.0–29.6)	28.5	(28.2–28.8)	-2.7 [¶]
Age group at diagnosis (yrs)		. ,		. ,		,		. ,		,	
0–39	1.9	(1.8–2.0)	2.0	(1.9–2.1)	2.0	(1.9-2.1)	1.9	(1.8–2.1)	1.9	(1.8–2.0)	0
40–49	41.4	(40.5-42.3)	41.8	(40.9-42.8)	42.1	(41.2-43.0)	41.9	(41.0-42.8)	42.9	(42.0-43.9)	2.4
50–59	69.9	(68.5-71.4)	72.0	(70.6–73.4)	73.1	(71.7–74.5)	73.7	(72.3-75.1)	69.9	(68.6-71.2)	-5.2¶
60–69	84.4	(82.5-86.3)	87.5	(85.6-89.4)	90.4	(88.5–92.3)	91.9	(90.0-93.8)	88.3	(86.4-90.1)	-3.9 [¶]
70–79	85.9	(83.9-88.0)	86.4	(84.4-88.5)	88.3	(86.2–90.3)	88.6	(86.6–90.7)	85.1	(83.1–87.2)	-4.0¶
<u>≥</u> 80	46.2	(44.3-48.1)	47.9	(46.1-49.8)	50.5	(48.6–52.4)	48.2	(46.4–50.0)	48.1	(46.4–50.0)	-0.2
Invasive	134.0	(133.3–134.6)	130.8	(130.2–131.4)	130.4	(129.8–131.0)	127.1	(126.5–127.7)	119.3	(118.7–119.9)	-6.1 [¶]
Age group at diagnosis (yrs)											
0–39	13.1	(12.8–13.4)	12.8	(12.5–13.1)	13.2	(12.9–13.5)	12.7	(12.4–12.9)	12.8	(12.6–13.1)	0.8
40–49	151.8	(150.0–153.6)	150.9	(149.1–152.7)	148.3	(146.6–150.0)	145.3	(143.6–147.0)	144.9	(143.2–146.5)	-0.3
50–59	284.3	(281.4–287.2)	278.5	(275.7–281.3)	278.5	(275.8–281.3)	269.1	(266.5-271.7)	249.1	(246.6–251.6)	-7.4¶
60–69	393.7	(389.7–397.7)	392.2	(388.2-396.2)	390.2	(386.2–394.2)	387.9	(384.0-391.9)	352.6	(348.9–356.4)	-9.1 [¶]
70–79	478.4	(473.7-483.2)	454.1	(449.4–458.7)	452.8	(448.1–457.4)	441.5	(436.9-446.1)	406.8	(402.3–411.2)	-7.9 [¶]
<u>≥</u> 80	439.0	(433.4–444.7)	419.4	(413.9-424.9)	417.8	(412.4–423.2)	399.5	(394.3-404.8)	369.3	(364.3–374.3)	-7.6 [¶]
Stage at diagnosis**											
Localized	82.1	(81.6-82.6)	79.4	(78.9-79.9)	79.1	(78.6–79.5)	77.2	(76.7-77.7)	71.9	(71.5–72.4)	-6.9¶
Regional	38.7	(38.3–39.0)	38.4	(38.1–38.8)	38.8	(38.5–39.2)	38.1	(37.7-38.4)	36.3	(36.0–36.6)	-4.7¶
Distant	5.9	(5.8–6.1)	5.8	(5.7–6.0)	5.7	(5.6–5.9)	5.5	(5.4–5.7)	5.4	(5.3–5.5)	-1.8
Unstaged	7.3	(7.1–7.4)	7.1	(7.0–7.3)	6.8	(6.6–6.9)	6.3	(6.2–6.5)	5.7	(5.5–5.8)	-9.5¶

* New cases diagnosed per 100,000 females, age adjusted to the 2000 U.S. standard population.

[†] Data are from 36 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* (1) for all years (1999–2003).

§ Confidence interval.

¹ Statistically significant (p<0.05) based on the rate ratio test in SEER*Stat comparing the 2003 rate with the 2002 rate.

** Stage at diagnosis according to SEER summary stage 1977 for cases diagnosed during 1999–2000 and SEER summary stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.


Decreases in rates of invasive female breast cancer from 2002 to 2003 were detected for all racial/ethnic populations analyzed except AI/ANs, although this population had the lowest overall incidence rate throughout the 5 years examined. In addition, the decrease in rates for black females was smaller than the decreases for other populations. Additional study is needed to determine possible reasons for these differences.


From 2002 to 2003, significant decreases occurred in incidence rates for localized, regional, and unstaged breast cancer but not distant breast cancer; the reason for the absence of a decrease in distant breast cancer is unknown. The 9.5% decrease in unstaged breast cancer cases might have resulted, in part, from more complete data collection about stage of disease at diagnosis, resulting in fewer unstaged cases. This finding is consistent with a SEER data analysis that attributed improvements in tumor staging to the substantial decrease (13.5 per 100,000 in 1975 to 4.9 per 100,000 in 2003) in unknown staged cases observed over the duration of the SEER program (4).

Several factors might affect breast cancer incidence and contribute to differences in rates over time and among populations. One such factor is hormone replacement therapy (HRT). Evidence collected, in part, through the National Institute of Health's Women's Health Initiative suggested an increased risk for invasive breast cancer among women who used HRT (5). The same year, the United States Preventive Services Task Force began recommending against the routine use of HRT (primarily combined estrogen and progestin regimens) for the prevention of chronic conditions, such as cardiovascular disease, in postmenopausal women.[¶] The mechanism by which HRT use might result in an increase in breast cancer incidence is unknown. One study suggested that hormones play a role in the promotion of breast carcinogenesis, increasing the rate at which certain preexisting but undetectable cancers grow (6). A population-based study in California of women aged 50–74 years who were members of a health-care plan determined that age-adjusted rates of hormone therapy decreased 68% from 2001 to 2003; during the same period, breast cancer incidence rates decreased 10% among the health-plan members and 11% among all women in California (7).

Because the breast cancer incidence rate began decreasing before 2002 (i.e., before the decrease in HRT use), other factors (e.g., differences in risk-factor prevalence, diet, and lifestyle) might be used to explain changes in breast cancer incidence rates. Mammography screening rates also might influence breast cancer incidence. A study in Connecticut that


⁹ United States Preventive Services Task Force. Recommendations and rationale: hormone replacement therapy for primary prevention of chronic conditions. Available at http://www.ahrq.gov/clinic/uspstf/uspspmho.htm.





- *New cases diagnosed per 100,000 females age adjusted to the 2000 _U.S. standard population.
- ⁺ Data for specified racial/ethnic populations other than white and black should be interpreted with caution because of possible misclassification. Hispanic origin is not mutually exclusive from race categories (i.e., white, black, Asian/Pacific Islander, and American Indian/Alaska Native).
- [§] Data are from 36 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide registries that meet data quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* (1) for all years (1999–2003).

FIGURE 2. Percentage change in incidence rates* for invasive female breast cancer, by state — United States,[†] 2002–2003



*New cases diagnosed per 100,000 females, age adjusted to the 2000 U.S. standard population. Only statistically significant changes in rates are shown. Statistically significant (p<0.05) based on the rate ratio test in _SEER*Stat comparing the 2003 rate with the 2002 rate.

analyzed breast cancer incidence rates during 1943-2002 indicated that although incidence rates increased over time, they increased more quickly after initiation of mammography screening recommendations in the early 1980s, suggesting that more cases were being detected through screening (8). Data from another recent report indicate that the number of women aged >40 years who reported having received a mammogram within the preceding 2 years decreased significantly, by 2.4%, from 2000 to 2005 (9). Similar decreases were indicated by National Health Interview Survey data; in 2003, 69.5% of women aged \geq 40 years had a mammogram within the preceding 2 years, compared with 70.4% in 2000.** Moreover, similar decreases in mammography screening rates were reported among persons enrolled in several types of health plans (i.e., commercial, Medicare, and Medicaid).^{††} The extent to which the decreases in mammography screening rates might affect breast cancer incidence is unknown.

The findings in this report are subject to at least four limitations. First, although the data are the most geographically comprehensive data available, data are not included from all U.S. states; therefore, some populations might not be well represented. Second, data for A/PIs, AI/ANs, and Hispanic populations might be underestimated because of misclassification in medical records. Third, no additional information about tumor characteristics (e.g., estrogen receptor status), screening, and risk factors was available in the data set used in this analysis; therefore, the role of such factors in the observed changes cannot be assessed. Finally, reporting delays for cancers, such as breast cancer, that are commonly diagnosed in outpatient settings might result in numerous additional cases being added to totals from previous years. NPCR and SEER registries require 2-3 years to compile and report complete information about cancer cases in their respective CDC and NCI databases. Revised and updated information about cancer cases for previous years are submitted to CDC and NCI each year along with current statistics. However, a recent study demonstrated no statistically significant difference between breast cancer incidence in the delay-adjusted trend compared with the non-delay-adjusted trend (2). Therefore, the nondelay-adjusted rates and trends described in this report are not expected to vary significantly because of reporting delays.

Analyses of future breast cancer incidence rates are needed to confirm the findings in this report. Studies should focus on examining possible causes for this decrease and analyzing 2004 data, which will become available in 2007.

⁺ Data are from 36 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide registries that meet dataquality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* (1) for all years (1999–2003). States not meeting these criteria were excluded.

^{**} National Center for Health Statistics. Health, United States, 2005. Available at http://www.cdc.gov/nchs/data/hus/hus05.pdf#086.

^{††} National Committee for Quality Assurance. The state of health care quality: industry trends and analysis. 2006. Available at http://www.ncqa.org/communications/ sohc2006/sohc_2006.pdf.

References

- US Cancer Statistics Working Group. United States cancer statistics: 2002 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, and National Cancer Institute; 2005. Available at http://apps.nccd.cdc.gov/uscs.
- Howe HL, Wu X, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/ Latino populations. Cancer 2006;107:1711–42.
- Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA, MD Anderson Cancer Center, National Cancer Institute, UCLA Medical Center. A decrease in breast cancer incidence in the United States in 2003. 29th Annual San Antonio Breast Cancer Symposium. December 2006. San Antonio, TX. Available at http://www.abstracts2view.com/ sabcs06/view.php?nu=SABCS06L_766.
- 4. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age an tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
- 5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
- Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Repro 2005;20:2052–60.
- Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence [Letter to the editor]. J Clin Oncol 2006;24:e49–50.
- Anderson WF, Jatoi I, Devesa SS. Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002). Breast Cancer Res Treat 2006;99:333–40.
- 9. CDC. Use of mammograms among women aged ≥40 years—United States, 2000-2005. MMWR 2007;56:49–51.

Hazardous Substances Released During Rail Transit — 18 States, 2002–2007

In January 2007, two separate railroad incidents involving the unintentional release of hazardous substances occurred on consecutive days in Irvine and Brooks, two Kentucky communities approximately 125 miles apart (1). Although the incidents were not causally related, they both resulted in public health consequences (e.g., increased hospital visits, evacuations, and shelter-in-place orders (Kentucky Department for Public Health, unpublished data, 2007). Subsequently, the Agency for Toxic Substances and Disease Registry (ATSDR) reviewed data from the Hazardous Substances Emergency Events Surveillance (HSEES) system to update a previous analysis involving rail events (2). The HSEES system is used to collect and analyze data regarding the public health consequences associated with hazardous-substance release events,* including those that occur during transportation. This report describes the two 2007 events in Kentucky (a non-HSEES state) and two other illustrative events in Minnesota in 2006 and in Utah in 2005, for which HSEES data were collected. In addition, this report summarizes all rail events reported to HSEES from 17 state health departments[†] during 2002–2006.[§]

Analysis of HSEES data was limited to the 78 rail events in which chemicals were released and the area of impact (i.e., the area where the plume extended) was \geq 200 feet from the point of release. This definition was chosen because of the greater likelihood that nearby populations might be affected, compared with incidents in which chemicals did not migrate beyond the point of release. The following four event reports were selected to highlight the public health consequences that can result from hazardous-substance releases.

Event Reports

Irvine, Kentucky. On January 15, 2007, four runaway train cars rolled approximately 20 miles before colliding with two unoccupied engines outside of Irvine, Kentucky (2000 population: 2,843). One of the four cars carried butyl acetate, a flammable solvent, which ignited on impact and resulted in an explosion. Butyl acetate can cause symptoms such as skin, eye, and upper respiratory system irritation; headache; drowsiness; and narcosis (3). After the crash, residents of 20 households were evacuated because of fumes and smoke produced by the burning butyl acetate, but they were allowed to return home later that day. Approximately 3,000 Irvine residents were advised to shelter in place (i.e., stay indoors and seal access to outside air). Approximately 320 employees of nearby businesses were evacuated for 2 days until air monitoring results confirmed conditions were no longer hazardous. No injuries were reported.

Brooks, Kentucky. On January 16, 2007, a train derailed in Brooks, Kentucky (2000 population: 2,678) (Figure). The derailment involved a total of 13 tank cars, 12 of which included hazardous materials or residue from hazardous materials. Tank cars containing 1,3-butadiene, cyclohexane, methyl ethyl ketone, and maleic anhydride were allowed to burn throughout the night to destroy the hazardous materials. These chemicals were detected in air and water samples from the area surrounding the incident site; soil and shallow groundwater also were assessed (4). The two-person train crew

^{*} An HSEES event is defined as one that involves the release or threatened release of a hazardous substance or hazardous substances that meet minimum criteria. A hazardous substance is one that can be expected to cause an adverse health effect.

[†] The analysis included events recorded in HSEES for 2002–2006. Twelve states participated in HSEES during the entire period: Colorado, Iowa, Louisiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Texas, Utah, Washington, and Wisconsin. Five additional states participated during portions of the period: Alabama (2002–2003), Florida (2005–2006), Michigan (2005–2006), Mississippi (2002–2003), and Missouri (2002–2005).

^{§ 2006} data are considered preliminary.

FIGURE. Train derailment involving the release of hazardous

substances — Brooks, Kentucky, January 2007

Photo/Michael Clevenger/Courier-Journal via The Associated Press

escaped unhurt. Thirty-one persons, examined <24 hours after the incident, had symptoms that included headache, dizziness, upper and lower respiratory tract irritation, and eye irritation. Fifty-three persons in the vicinity eventually sought medical treatment at two local hospitals. A woman aged 61 years with a history of chronic obstructive pulmonary disease (COPD) was transferred to a metropolitan hospital with exacerbation of her COPD symptoms because of smoke inhalation. She was released after 2 weeks of supportive therapy.

After this incident occurred, approximately 350 persons from homes, schools, and businesses within a 1-mile radius of the release site were evacuated for 2 hours. Thirty-five residents of 15 homes were prohibited from returning home for approximately 6 weeks until contaminated plastic water lines (penetrable by released chemicals) were replaced. Approximately 300 persons from outside the evacuation area but within the path of the plume were ordered to shelter in place. In addition, an 8-mile stretch of an interstate highway approximately 0.5 mile from the release site and in the path of the plume was closed for 12 hours (5).

St. Paul, Minnesota. In May 2006, approximately 5,000 gallons of hydrochloric acid were released in St. Paul, Minnesota (2000 population: 287,151), from a stationary rail tanker at a chemical wholesaler. The rubber liner in the tanker had become displaced, allowing the acid to corrode and rupture the bottom of the tanker. A vapor cloud drifted from the site, and approximately 150 gallons of acid traveled through a storm sewer to a nearby river. Hydrochloric acid can cause skin, eye, and respiratory irritation; burns; and pulmonary edema (3). Seven persons were reported injured after contact with the vapor cloud: six members of the general public and one employee of the wholesaler. The most common injuries were respiratory and eye irritation. Six of the injured were treated at a hospital and released; the seventh person had symptoms but was not treated. Approximately 100 persons downwind from the release and in the path of the subsequent vapor cloud were evacuated for 2 hours. A shelter-in-place order was issued for other sites near the 1-square-mile evacuation area.

Salt Lake City, Utah. In March 2005, a mixture of approximately 6,500 gallons of phosphoric, sulfuric, acetic, and hydrofluoric acids corroded the inside of a stationary railcar and began leaking, causing an orange vapor cloud in Salt Lake City, Utah (2000 population: 181,743). The corrosion was attributed to improper combination of the acids because of human error. A member of the general public approximately 0.25 mile away experienced respiratory irritation and was treated on the scene. Approximately 8,000 persons downwind from the release were evacuated for 5 hours, and a shelter-in-place order was issued for a five-block area near the evacuation zone.

HSEES Surveillance of Rail Events

State health departments participating in HSEES collect data on acute hazardous-substance events from various agencies, including the National Response Center, U.S. Department of Tranportation, and state environmental and response agencies. The data are immediately entered into a secure Internet database, from which they can be accessed by ATSDR and the states. Of the 42,359 hazardous-substance releases reported to HSEES by 17 state health departments during 2002-2006, a total of 11,383 (26.9%) were transportation related, including 1,051 (9.2%) that involved rail transport. Among the rail transport events, 78 (7.4%) involved a chemical release and an area of impact that extended ≥ 200 feet from the point of release. The most common primary contributing factor in these 78 events was equipment failure (49 events [62.8%]); human error contributed to 24 (30.8%) events. A total of 103 different substances were released in the 78 rail transport events. The most common substances were diesel fuel (released along with a hazardous chemical substance) (seven events), chlorine (five), and hydrochloric acid (five); 61 (78.2%) events involved release of a single chemical.

Injuries were reported from 11 (14.1%) of the 78 rail events; a total of 144 persons were injured (Table). Among those injured, 101 (70.1%) were members of the general public, 27 (18.8%) were employees of the railroad or companies at the sites of releases, and 16 (11.1%) were responders. Of the 210 total injuries sustained by the 144 persons, the most commonly reported were respiratory irritation (104 [49.5%]) and eye irritation (33 [15.7%]). Among the 143 persons for whom medical outcome was known, 101 (70.6%) were treated at hospitals and released, and 23 (16.1%) were treated on the scene. Nine (6.3%) persons were admitted to a hospital, five (3.5%) were examined at a hospital but not treated, and two

554

TABLE. Number of rail events (N = 78) in which chemicals were released and the area of impact (i.e., extension of plume) was \geq 200 feet from the point of release, by selected characteristics — Hazardous Substances Emergency Events Surveillance system, 2002–2006*

Characteristic	No.	%
Sensitive sites within 0.25 mile		
Residences	63	80.8
Day care centers	8	10.3
Schools	8	10.3
Nursing homes	3	3.8
Responding groups [†]		
Railroad response team	60	76.9
Law enforcement	33	42.3
Certified hazardous materials team	33	42.3
Fire department	31	39.7
Response activities		
Evacuation ordered	17	21.8
Shelter in place ordered	8	10.3
Decontamination conducted	9	11.5
No evacuation, shelter-in-place, or		
decontamination	58	74.4
Types of injuries reported by persons [§]		
(N = 144) from all events (N = 11) with injur	ies	
Respiratory	104	49.5
Eye	33	15.7
Headache	23	11.0
Dizziness/Central nervous system	16	7.6
Gastrointestinal	16	7.6
Other injuries	18	8.5

* Includes events from Alabama, Colorado, Florida, Iowa, Louisiana, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New York, North Carolina, Oregon, Texas, Utah, Washington, and Wisconsin.

[†] For most events, more than one group responded; however, no group responded in three events.

[§] Some persons reported more than one injury.

(1.4%) had symptoms but were not treated. Three persons died; a railroad employee died from trauma, and two members of the general public died from respiratory injuries.

In the 78 events, a total of 314,336 residents (range: zero to 25,480 persons; median: 2,765) lived within 1 mile of the release sites. In 63 (80.8%) of the events, residences were located within 0.25 mile of the release, affecting a total 16,074 residents (range: 0–1,820 persons; median: 123). Sensitive sites located within the 0.25-mile range included day care centers (eight), schools (eight), and nursing homes (three) (Table). Seventeen (21.8%) rail events were associated with mandatory evacuations. A total of 10,002 persons (range: seven to 8,000 persons; median: 48) were known to have been evacuated. Durations of evacuation ranged from <1 hour to 13 days (median: 5.8 hours). For 58 (74.4%) rail events, no orders were issued to evacuate or shelter in place.

Reported by: *B Learn, D Thoroughman, PhD, Kentucky Dept for Public Health. R Brackbill, PhD, DK Horton, MSPH, PZ Ruckart,* MPH, F Bove, ScD, M Orr, MS, V Kapil, DO, Div of Health Studies, Agency for Toxic Substances and Disease Registry.

Editorial Note: Approximately 1.8 million carloads of hazardous substances are shipped annually by rail in the United States, including through densely populated or environmentally sensitive areas (6–8). Of these carloads, approximately 105,000 contain toxic inhalation hazard substances such as chlorine, anhydrous ammonia, and hydrochloric acid (6,7). Although rail events constitute only 2% of total hazardoussubstance releases in HSEES, releases during rail transit can cause severe public health consequences, as demonstrated by the event reports and surveillance data. Notably, approximately 81% of hazardous-substance releases from rail events occurred in areas with residences within 0.25 mile, and most of the injured were members of the general public.

Although the rate of all rail incidents has declined sharply since 1980, less improvement has been observed in recent years; the rail incident rate per million train miles actually increased from 3.76 in 2002 to 4.38 in 2004, before decreasing to 4.08 in 2005 (6). In recent years, concern over railroad safety has been elevated by major incidents such as the Graniteville, South Carolina, train collision in January 2005 that released 11,500 gallons of chlorine gas, caused nine deaths, and resulted in 529 persons seeking medical treatment (2,6). In response, the U.S. Department of Transportation (DOT) and the Federal Railroad Administration launched the National Rail Safety Action Plan in 2005 (9). This plan targets the most frequent, highest-risk causes of train incidents (e.g., equipment failure or human error) and is aimed at improving emergency preparedness and the safe handling of hazardous materials. In addition, in 2006, DOT proposed new rules requiring rail carriers to compile annual data on hazardous materials shipments and use these data to evaluate safety and security risks and alternative routing options (7).

The findings in this report are subject to at least four limitations. First, HSEES data were collected from only 17 states; therefore, the data represent only a proportion of hazardoussubstance events that occur in the United States. Second, HSEES data do not fully integrate data on hazardoussubstance releases that are collected by federal and state agencies. Moreover, acute release data are not effectively linked to other public health and environmental data (e.g., population, demographics, and locations of schools, nursing homes, and day care centers). Improved surveillance might place hazardous-substance incidents in community and industry contexts and enable more thorough analyses of the causes and effects of incidents. Third, reporting of events to HSEES is not mandatory, and participating state health departments are not informed about every event. Finally, by law, petroleumonly releases are excluded from HSEES data collection.

Additional preparedness measures (e.g., planning and training of local response agencies and the public and establishment of notification mechanisms, escape routes, shelter-in-place protocols, and emergency shelters) are needed to respond to hazardous-substance rail incidents. In addition, new concerns have been raised since September 11, 2001, regarding the potential for terrorist attacks on railcars carrying large quantities of hazardous substances. Increased collaboration among railroad stakeholder organizations (e.g., environmental, transportation, industry, public health, public safety, and research) could result in better mechanisms to monitor rail substance-release events and use available data to identify vulnerabilities and promote safer technologies and practices.

Acknowledgments

The findings in this report are based, in part, on contributions by participating HSEES states; Kentucky Dept for Public Health; D Reeves, US Dept of Transportation; and B Lewis, Agency for Toxic Substances and Disease Registry.

References

- US Environmental Protection Agency, Region 4. Train derailment in Brooks, Bullitt County, KY. Atlanta, GA: U.S. Environmental Protection Agency; 2007. Available at http://www.epa.gov/region4/brooks_ky/ updates.html.
- CDC. Public health consequences from hazardous substances acutely released during rail transit—South Carolina, 2005; selected states, 1999– 2004. MMWR 2005;54:64–7.
- National Institute for Occupational Safety and Health. NIOSH pocket guide to chemical hazards. Cincinnati, OH: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 2004. Available at http://www.cdc.gov/niosh/npg.
- US Environmental Protection Agency, Region 4: Southeast. Unified command—information update: CSX transportation derailment site— Brooks, Kentucky. Atlanta, GA: US Environmental Protection Agency; 2007. Available at http://www.epa.gov/region4/brooks_ky/unified_ command.html.
- US Environmental Protection Agency, Region IV. CSX derailment— Brooks, KY, pollution report. Atlanta, GA: US Environmental Protection Agency, 2007. Available at http://www.epaosc.net/polrep_ profile.asp?site_id=2749.
- 6. US Department of Transportation. Written statement of Michael T. Haley, deputy chief counsel, U.S. Department of Transportation, before the subcommittee on transportation security and infrastructure protection, committee on homeland security, US House of Representatives. Hearing on update on federal rail and public transportation security efforts, 2007. Available at http://homeland.house.gov/ SiteDocuments/20070206172402-34557.pdf.
- 7. US Department of Transportation. Federal Register 2006;245:76834-6.
- Horton DK, Berkowitz Z, Haugh GS, Orr MF, Kaye WE. Acute public health consequences associated with hazardous substances released during transit, 1993–2000. J Hazard Mater 2003;98:161–75.
- Federal Railroad Administration. National rail safety action plan. Washington, DC: US Department of Transportation, Federal Railroad Administration; 2005. Available at http://www.fra.dot.gov/us/content/ 1554.

West Nile Virus Activity — United States, 2006

West Nile virus (WNV) is the leading cause of arboviral encephalitis in the United States. Originally discovered in Africa in 1937, WNV was first detected in the western hemisphere in 1999 in New York City. Since then, WNV has caused seasonal epidemics of febrile illness and severe neurologic disease in the United States. This report summarizes provisional WNV surveillance data for 2006 reported to CDC as of April 3, 2007. During 2006, WNV transmission to humans or animals expanded into 52 counties that had not previously reported transmission and recurred in 1,350 counties where transmission had been reported in previous years. In addition, 1,491 cases of WNV neuroinvasive disease (WNND) were reported in the United States during this period, amounting to a 14% increase from 2005 and the largest number reported since 2003. On the basis of extrapolations from past serosurveys, an estimated 41,750 cases of non-neuroinvasive WNV disease occurred in 2006; of these cases, 2,770 were reported. These findings highlight the need for ongoing surveillance, mosquito control, promotion of personal protection from mosquito bites, and research into additional prevention strategies.

WNV data are reported to CDC through ArboNET, an Internet-based arbovirus surveillance system managed by state health departments and CDC. State and local health departments 1) collect reports from health-care providers and clinical laboratories regarding cases of WNV disease in humans; 2) collect and test dead birds, often focusing on corvids (e.g., crows, jays, and magpies), which have high mortality attributed to WNV infection; 3) collaborate with veterinarians to collect reports of WNV infection in nonhuman mammals; and 4) collect mosquitoes to test for evidence of WNV infection. Human WNV disease cases are classified as 1) WNND (i.e., meningitis, encephalitis, or acute flaccid paralysis); 2) West Nile fever (WNF), which is symptomatic WNV disease that does not affect the nervous system; 3) other clinical illness; or 4) unspecified (i.e., unknown) illness. WNF reporting is highly variable by jurisdiction, depending on the level of interest in reporting and utilization of diagnostic testing; therefore, this report focuses on WNND cases, which are thought to be more consistently identified and reported because of the severity of the illness.

Human Surveillance


During 2006, a total of 4,261 cases of WNV disease in humans were reported from 731 counties in 43 states and the District of Columbia, accounting for 23.3% of the 3,142 counties in the United States. Of these cases, 1,491 were WNND, 2,612 were WNF, and 158 were unspecified illnesses. Idaho, a state that reported four WNND cases (from a total of 17 human cases) during 2003–2005, reported 139 WNND cases in 2006, accounting for 9.3% of the national total. Idaho first reported any WNV activity in 2002; the first human case in the state was reported in 2003. Other focal outbreaks of WNND occurred in states that experienced outbreaks in previous years, including Texas (229 WNND cases), Illinois (127), Louisiana (91), and Mississippi (89). In the New York City metropolitan area, WNV disease recurred for the eighth consecutive year, with eight WNND cases reported. The counties with the highest incidence of WNND were primarily in the west-central United States (Figure 1). The states with the highest incidence included Idaho (9.9 cases per 100,000 residents), South Dakota (4.9), and North Dakota (3.2). The incidence of WNND peaked during the first week in August, and the overall trend was consistent with the seasonality observed in the preceding 6 years (Figure 2).

The median age of the 1,491 persons with WNND was 58 years (range: 3 months–99 years), and 891 (59.8%) were male. A total of 1,311 (87.9%) persons were hospitalized, and 161 (10.8%) died. A total of 101 (6.8%) persons with WNND had acute flaccid paralysis; the median age among these persons was 53 years (range: 1–87 years), and 62 (61.4%) were male. Twelve (11.9%) died; the median age of these persons was 76 years (range: 19–99 years).

Animal Surveillance

In 2006, a total of 4,106 dead WNV-infected birds were reported from 701 counties in 43 states; 404 counties from





* Per 100,000 county residents.

^TMeningitis, encephalitis, or acute flaccid paralysis.

⁹ Provisional data as of April 3, 2007.

38 states reported infected birds but no human disease. Collection of WNV-infected birds peaked during mid-August. Corvids accounted for 3,292 (80%) of the birds; the majority of states targeted corvids for surveillance. Since 1999, WNV infection has been identified in approximately 300 avian species, including 11 species in which WNV was identified for the first time during 2006.

Of 1,121 reported WNV disease cases among nonhuman mammals, 1,086 (96.9%) occurred in equine animals, and 35 (3.2%) occurred in other species (squirrels [33] and unspecified species [two]). Equine cases were reported from 414 counties in 34 states; Idaho reported 31% of all equine cases. Peak reported incidences of equine disease occurred during mid-August.


A total of 11,898 mosquito pools* from 459 counties in 38 states and the District of Columbia tested positive for WNV. Among the WNV-positive pools, 8,665 (72.8%) were made up of *Culex* mosquitoes thought to be the principal vectors of WNV transmission (i.e., *Cx. pipiens, Cx. quinquefasciatus, Cx. restuans, Cx. salinarius,* and *Cx. tarsalis*) (1). Unidentified or other species of *Culex* mosquitoes made up 3,032 (25.5%) pools, and non-*Culex* species (i.e., *Aedes* spp., *Anopheles* spp., *Coquillettidia* spp., *Culiseta* spp., *Ochlerotatus* spp., and *Psorophora* spp.) made up 135 (1.1%) pools. Data from 2006 included the first report of WNV infection in *Culex apicalis,* which was collected in Arizona. The number of reported WNV-infected mosquito pools peaked during the first week in August.


Reported by: NP Lindsey, MS, JA Lehman, EB Hayes, MD, RS Nasci, PhD, N Komar, ScD, LR Petersen, MD, Div of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.

Editorial Note: In 2006, a total of 1,491 cases of WNND were reported, the highest number reported since 2003.[†] WNV activity was detected in all 48 contiguous states for the second consecutive year. Human WNV disease was scattered throughout the United States, but the majority of cases were reported in Idaho and in the west-central states. One state (Washington) reported human cases for the first time. The increase in reported cases since 2004 suggests that endemic transmission of WNV in the United States will continue. Although WNND case reports from Idaho (a state that reported only four WNND cases during 2003–2005) accounted for nearly 10% of all WNND cases reported in 2006, focal outbreaks also recurred in areas where seasonal transmission has occurred for several years (*1*).

^{*} A sample of mosquitoes (usually no more than 50) of the same species and sex, collected within a defined sampling area and period.

[†] Additional information available at http://www.cdc.gov/ncidod/dvbid/westnile/ surv&control.htm.





* N = 9,902.

[†] Meningitis, encephalitis, or acute flaccid paralysis.

§ Provisional data as of April 3, 2007.

[¶] Council of State and Territorial Epidemiologists.

** West Nile virus was first detected in the United States in August 1999. The ArboNET surveillance system was established in 2000.

This report focuses on WNND cases because of the variability in WNF reporting by jurisdiction and by year. Reporting of WNND is thought to be more consistent and complete because of the higher likelihood of hospitalization and testing. Although the Council of State and Territorial Epidemiologists designated WNF as a notifiable disease in 2005, the true incidence and public health impact of WNF remains underestimated by national surveillance data (2,3). Populationbased serologic surveys indicate that approximately 140 WNV infections occur for every case of WNND and that of all persons who become infected, approximately 20% have onset of WNF and 80% remain asymptomatic (2, 4). By applying these ratios to the 1,491 reported WNND cases, an estimated 208,700 cases of WNV infection (1,491 WNND cases × 140) and 41,750 cases of WNF (208,700 × 0.20; only 2,612 cases were reported) occurred in the United States in 2006.

Although persons of all ages appear equally susceptible to WNV infection, both the incidence of WNND and the incidence of death related to WNND increase with age, especially among persons aged >60 years, and are slightly higher among males (1,5). During 2006, the median age among persons with fatal WNND was similar to that of previous years (4,6).

Reports of WNV disease in equine animals have decreased annually since 2002 (CDC, unpublished data, 2007). Whether this decline represents a true decrease in disease incidence resulting from naturally acquired immunity or vaccination (7) or is a result of reduced emphasis on equine WNV disease reporting is not clear. Nonetheless, the temporal and geographic distribution of equine WNV cases continues to correlate with human cases, suggesting that surveillance of equine animals can continue to help indicate areas of increased risk for human WNV disease.

Since 1999, corvids have accounted for the majority (>70%) of all WNVinfected dead birds reported to CDC. The substantial number of reported corvid deaths likely results from the size of corvids and their susceptibility to WNV disease and from surveillance programs specifically targeted at corvids. Geographically, surveillance of WNV in different bird species can vary in usefulness as indicators for WNV transmission; targeting locally relevant species can optimize efficiency of WNV surveillance.

As of December 31, 2006, WNV had been detected in 62 of the approximately 175 mosquito species found in

the United States. In 2006, *Culex* mosquitoes (specifically *Cx. pipiens, Cx. quinquefasciatus, Cx. restuans, Cx. salinarius,* and *Cx. tarsalis*) continued to be the most prevalent in WNV-positive pools. Although 33 different WNV-infected mosquito species were identified in 2006, *Culex* mosquitoes are believed to account for the majority of WNV transmission in the United States (1). Therefore, *Culex* mosquitoes remain the primary vector target for prevention of WNV disease in the United States.

WNV surveillance is important for monitoring further spread of the virus and targeting prevention and control strategies. The ArboNET surveillance system focuses on arboviral diagnosis, testing, and reporting and is well positioned to detect increased transmission of all domestic arboviruses, to identify future introduction of foreign arboviruses, and to monitor effects of climate and other determinants of arboviral disease incidence.

In the absence of an effective human vaccine, prevention of WNV disease depends on community-level mosquito control (e.g., larviciding, adulticiding, and breeding-site reduction) and promotion of personal protection against mosquito bites, such as use of repellents and avoiding outdoor exposure when mosquitoes are most active (usually from dusk to dawn). Repellents containing DEET, picaridin, or oil of lemon eucalyptus provide protection against mosquito bites. Intact window screens or air conditioning can reduce mosquito exposure in homes. Numbers of mosquitoes can be reduced by removing or emptying water from larval habitats such as flower pots, buckets, gutters, and barrels.

Acknowledgments

This report is based, in part, on data provided by ArboNET surveillance coordinators in local and state health departments and ArboNET technical staff, Div of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, CDC.

References

- 1. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005;11:1167–73.
- 2. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261-4.
- Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004;141:360–5.
- 4. Tsai TF, Popovici F, Cernescu, et al. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998;352:767–71.
- O'Leary DR, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004;4:61–70.
- 6. CDC. West Nile virus activity—United States, 2001. MMWR 2002;51:497-501.
- Davidson AH, Traub-Dargatz JL, Rodeheaver RM, et al. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J Am Vet Med Assoc 2005;226:240–5.

Notice to Readers

Heads Up! Tool for Diagnosing and Managing Brain Injury

An estimated 75%–90% of the 1.4 million traumatic brain injury–related deaths, hospitalizations, and emergency department visits that occur each year in the United States are concussions or mild traumatic brain injuries (MTBIs) (1-5). Clinicians can help prevent MTBI or concussion and improve patient health outcomes with early diagnosis, management, and appropriate referral. However, diagnosing MTBIs can be challenging because certain symptoms are similar to those of other medical conditions (e.g., posttraumatic stress disorder, depression, and headache syndromes), and the onset or recognition of symptoms might not occur until days or weeks after the injury (6).

To aid clinicians in the diagnosis and management of MTBIs, CDC recently updated and revised the Heads Up: Brain Injury in Your Practice tool kit. The free tool kit can be ordered or downloaded at http://www.cdc.gov/ncipc/tbi/physicians_tool_kit.htm. Additional information regarding MTBI is available at http://www.cdc.gov/injury, or by e-mail, cdcinfo@cdc.gov, or telephone, 800-CDC-INFO (800-232-4636).

References

- CDC. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/ncipc/pub-res/tbi_in_us_04/tbi_ed.htm.
- CDC. Report to Congress on mild traumatic brain injury in the United States: steps to prevent a serious public health problem. Atlanta, GA: US Department of Health and Human Services. CDC; 2003.
- 3. Kraus JF, Nourjah P. The epidemiology of mild, uncomplicated brain injury. J Trauma 1988;28:1637–43.
- Luerssen TG, Klauber MR, Marshall LF. Outcome from head injury related to patient's age: a longitudinal prospective study of adult and pediatric head injury. J Neurosurg 1988;68:409–16.
- 5. Lescohier I, DiScala C. Blunt trauma in children: causes and outcomes of head versus intracranial injury. Pediatrics 1993;91:721–5.
- 6. Kushner D. Mild traumatic brain injury: toward understanding manifestations and treatment. Arch Intern Med 1998;158:1617–24.

Erratum: Vol. 56, No. 18

In the report, "Characteristics of Persons with Chronic Hepatitis B — San Francisco, California, 2006," on page 446, the last sentence of the second paragraph should read, "A probable case is defined as an infection in a person with a single HBsAg-positive, HBV DNA-positive, or HBeAg-positive laboratory result with no IgM anti-HBc test reported." TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending June 2, 2007 (22nd Week)*

	Current	Cum	5-year weekly	Total c	ases rep	orted for	previou	s years	
Disease	week	2007	average [†]	2006	2005	2004	2003	2002	States reporting cases during current week (No.)
Anthrax	_	_	_	1	_	_	_	2	
Botulism:									
foodborne	—	2	0	20	19	16	20	28	
infant	_	29	2	97	85	87	76	69	
other (wound & unspecified)	—	8	1	48	31	30	33	21	
Brucellosis	—	48	2	119	120	114	104	125	
Chancroid	—	10	1	33	17	30	54	67	
Cholera	_		0	9	8	5	2	2	
Cyclosporiasis§	1	26	13	136	543	171	75	156	FL (1)
Diphtheria Domestic arboviral diseases ^{s.1} :	_	_	_	_	_	_	1	1	
California serogroup	_	_	0	63	80	112	108	164	
eastern equine	_	_	0	7	21	6	108	104	
Powassan	_	_	_	1	1	1		1	
St. Louis	_	_	0	9	13	12	41	28	
western equine	_	_	_	_					
Ehrlichiosis [§] :									
human granulocytic	3	24	10	644	786	537	362	511	MN (2), MO (1)
human monocytic	7	57	6	548	506	338	321	216	MN (3), MD (2), NC (2)
human (other & unspecified)	1	21	3	234	112	59	44	23	MD (1)
Haemophilus influenzae,**									
invasive disease (age <5 yrs):									
serotype b	—	5	0	17	9	19	32	34	
nonserotype b	3	37	2	139	135	135	117	144	NC (2), OK (1)
unknown serotype	2	108	4	228	217	177	227	153	PA (1), UT (1)
Hansen disease§	1	20	2	66	87	105	95	96	MN (1)
Hantavirus pulmonary syndrome [§]	1	7	1	38	26	24	26	19	WA (1)
Hemolytic uremic syndrome, postdiarrheal§	_	37	4	286	221	200	178	216	
Hepatitis C viral, acute	7	253	20	824	652	713	1,102	1,835	MI (1), MO (1), KY (1), OK (2), TX (2)
HIV infection, pediatric (age <13 yrs) ⁺⁺	_		4	52	380	436	504	420	
Influenza-associated pediatric mortality ^{§,§§}	5 4	65	0	41	45	75.0	N	N	TX(5)
Listeriosis Measles ¹¹¹	4	195 14	12 2	873 74	896 66	753 37	696 56	665 44	MN (1), NC (1), TX (1), WA (1)
Meningococcal disease, invasive***:	_	14	2	74	00	37	50	44	
A, C, Y, & W-135	2	119	6	288	297	_	_	_	SD (1), MD (1)
serogroup B	1	44	3	182	156	_	_	_	FL (1)
other serogroup		9	0	29	27	_	_	_	1 = (1)
unknown serogroup	4	303	15	685	765	_	_	_	PA (1), DE (1), ID (1), OR (1)
Mumps	5	391	44	6,587	314	258	231	270	OH (1), MI (1), MN (1), KS (1), FL (1)
Novel influenza A virus infections	_	_	_	N	N	N	Ν	N	
Plague	_	1	0	17	8	3	1	2	
Poliomyelitis, paralytic	_	_		_	1	_	_	—	
Poliovirus infection, nonparalytic§	—	_	_	N	N	N	N	N	
Psittacosis§	—	3	0	21	16	12	12	18	
Q fever [§]	1	69	3	175	136	70	71	61	NC (1)
Rabies, human	—	_	0	3	2	7	2	3	
Rubellattt	—	8	0	10	11	10	7	18	
Rubella, congenital syndrome	—	_		1	1	—	1	1	
SARS-CoV ^{\$,\$§§}	—	_	0	_	_	_	8	N	
Smallpox [§]				105					
Streptococcal toxic-shock syndrome [§]	4	39	3 8	125	129	132	161	118	OH (3), IN (1)
Syphilis, congenital (age <1 yr)	_	88		380	329	353	413	412	
Tetanus Toxic-shock syndrome (staphylococcal)§	1	4 30	1 2	40 100	27 90	34 95	20 133	25 109	IN (1)
Trichinellosis		30	2	100	90 16	95 5	6	109	11 v (1 <i>)</i>
Tularemia	1	11	3	99	154	5 134	0 129	90	MO (1)
Typhoid fever	_	105	6	346	324	322	356	321	
Vancomycin-intermediate Staphylococcus au	reus [§] —	3	0	540 6	2	522	330 N	N	
Vancomycin-resistant Staphylococcus aureus			0	1	3	1	N	N	
Vibriosis (non-cholera <i>Vibrio</i> species infection		70	1	Ň	Ň	Ň	N	N	FL (2), CA (2)

-: No reported cases. Cum: Cumulative year-to-date counts. N: Not notifiable.

§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 66 cases were reported for the 2006–07 flu season. 11 No measles cases were reported for the current week. Data for meningococcal disease (all serogroups) are available in Table II. ***

+++

No rubella cases were reported for the current week. Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. §§§

(22nd Week)*			Chlamyd	lia†			Coccid	lioidomy	cosis			Cryp	otosporio	liosis	
			vious					vious	-				vious		
Reporting area	Current week	Med	veeks Max	Cum 2007	Cum 2006	Current week	Med	weeks Max	Cum 2007	Cum 2006	Current week	Med	veeks Max	Cum 2007	Cum 2006
United States	6,567	19,960	25,263	386,393	422,364	106	152	658	3,364	3,665	31	69	325	1,021	1,140
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§] Vermont [§]	778 374 49 269 3 72 11	670 204 47 309 38 65 20	1,357 829 73 600 69 108 45	14,214 3,769 1,091 6,782 760 1,450 362	13,072 3,259 888 6,231 771 1,396 527	N N	0 0 0 0 0 0	0 0 0 0 0 0	N - - N	N N		5 0 2 1 0 1	40 11 6 29 4 5 4	63 11 10 18 11 5 8	106 38 13 39 12 1 3
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	957 — 564 393	2,571 379 509 761 811	4,284 541 2,758 1,521 1,788	57,395 5,132 10,361 18,809 23,093	51,858 8,022 9,527 17,730 16,579	N N N	0 0 0 0	0 0 0 0	N N N	N N N N	5 — — 5	10 0 3 2 3	37 5 14 10 18	126 — 43 22 61	179 9 35 55 80
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	834 293 417 49 75	3,160 981 381 740 656 371	6,231 1,290 644 1,225 3,647 528	69,516 18,565 8,651 15,567 19,074 7,659	72,203 22,958 8,634 13,252 18,244 9,115	1 — — 1 N	1 0 1 0	3 0 3 2 0	14 10 N	17 13 N	6 4 1 1	15 2 1 3 5 4	110 22 18 10 33 53	227 19 20 57 75 56	253 36 20 37 84 76
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	356 119 147 — 46 — 44	1,188 167 147 244 434 105 30 49	1,448 243 312 314 628 184 69 84	19,692 3,642 3,322 3,866 5,220 2,152 446 1,044	25,765 3,519 3,454 5,452 9,392 2,072 778 1,098	N N N N N	0 0 0 0 0 0 0	54 0 54 1 0 0	3 N N 3 N N N	N N N N N	9 1 6 1 1	11 2 1 2 1 0 1	77 28 25 21 16 11 7	161 27 24 44 32 6 1 27	175 17 23 67 34 12 2 20
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	1,236 31 85 486 270 340 24	3,630 69 80 916 691 394 631 426 495 55	6,760 111 167 1,087 3,822 677 1,207 2,105 685 83	59,759 1,385 2,348 3,300 9,211 7,792 12,643 11,440 10,528 1,112	80,818 1,492 1,277 20,112 14,527 8,508 14,969 8,939 9,750 1,244		0 0 0 0 0 0 0 0 0 0	1 0 0 1 0 0 0 0 0	1 N N 1 N N N	2 N N 2 N N N N	7 	18 0 9 4 0 1 1 0	70 3 2 32 17 2 11 14 5 3	259 2 3 132 48 11 26 17 17 3	248 1 7 101 72 6 29 13 17 2
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	692 — 115 118 459	1,395 367 136 405 531	2,044 539 691 959 699	26,703 2,079 3,233 9,324 12,067	31,883 10,200 3,954 7,253 10,476	N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	1 1 —	3 0 1 0 1	14 11 3 8 5	48 18 15 8 7	41 14 11 5 11
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	124 124 	2,169 167 321 256 1,451	3,028 337 610 472 1,911	45,380 3,464 6,599 5,190 30,127	47,544 3,382 7,166 4,963 32,033	N N N	0 0 0 0	1 0 1 0	N N N	N N N	1 1 	5 0 1 1 2	45 3 9 9 36	37 2 14 16 5	61 6 12 12 31
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	241 11 95 — 38 — 87 10	1,334 463 299 43 53 167 176 97 26	2,026 993 416 253 144 397 396 200 45	22,811 6,508 4,131 1,263 1,116 3,439 3,843 2,017 494	27,195 8,198 6,605 1,387 911 3,132 4,297 2,038 627	78 78 N N 	99 98 0 0 1 0 1 0	293 293 0 0 3 3 4 0	2,275 2,226 N N 18 7 24 —	2,571 2,495 N N 34 11 29 2	2 2 	5 0 1 0 0 1 0 0	40 5 7 26 3 6 3 11	72 14 23 4 4 4 14 2 7	45 5 11 4 7 3 9 6
Pacific Alaska California Hawaii Oregon [§] Washington	1,349 74 894 381	3,355 88 2,654 106 160 339	4,362 157 3,627 130 394 621	70,923 1,813 55,531 2,143 3,818 7,618	72,026 1,761 56,057 2,427 4,077 7,704	27 N 27 N N N	53 0 53 0 0	311 0 311 0 0 0	1,071 N 1,071 N N	1,075 N 1,075 N N N	 	1 0 0 1 0	5 1 0 1 5 0	28 — — 28 —	32 1 31
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U — U	0 16 122 3	21 24 234 10	U U 3,041 U	U U 381 2,056 U	U U N U	0 0 0 0	0 0 0 0	U U N U	U U N U	U U N U	0 0 0 0	0 0 0 0	U U N U	U U N U

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. Chamydia refers to genital infections caused by *Chlamydia trachomatis*. S Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardiasi	s				onorrhe	a		Hae	All age	s, all ser	z <i>ae</i> , invas otypes†	ive
	Current	Prev 52 w		Cum	Cum	Current		evious weeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	83	300	1,501	5,288	6,353	1,956	6,666	8,896	121,962	143,903	20	46	177	984	1,023
New England Connecticut	4	26 5	68 25	376 99	606 109	156 86	109 43	259 204	2,273 792	2,249 820	_	3 0	19 6	67 20	94 18
Maine [§]	3	4	14	53	35	1	2	8	45	51	_	0	4	6	7
Massachusetts New Hampshire	_	12 0	39 3	157 4	357 10	65	48 2	96 8	1,154 62	1,049 99	_	2 0	8 2	36 4	56 5
Rhode Island [§] Vermont [§]	1	0 3	17 12	23 40	36 59	3 1	9 1	19 5	199 21	205 25	_	0 0	10 1	1	2 6
Mid. Atlantic	2	62	127	914	1,249	248	683	1,537	14,943	13,639	3	10	27	209	203
New Jersey New York (Upstate)	—	7 25	17 108	36 347	189 398	_	103 121	155 1,035	1,483 2,349	2,216 2,502	_	1 3	5 15	17 59	37 55
New York City	_	16	32	299	391	119	181	376	4,058	4,271	_	2	6	41	38
Pennsylvania E.N. Central	2 7	14 44	34 100	232 728	271 1,014	129 334	250 1,297	609 2,588	7,053 27,511	4,650 28,935	3 1	3 6	10 15	92 102	73 175
Illinois	_	11	30	103	252	_	352	485	6,609	8,389	_	1	6	11	55
Indiana Michigan	N 2	0 14	0 38	N 248	N 274	127 156	156 295	292 880	3,475 6,349	3,728 5,344	_	1 0	10 5	20 12	33 18
Ohio Wisconsin	5	15 9	32 27	277 100	296 192	21 30	334 131	1,566 181	8,385 2,693	8,501 2,973	1	2 1	6 4	52 7	35 34
W.N. Central	8	21	553	338	681	83	386	517	5,846	7,781	2	3	24	62	52
lowa Kansas	4	5 3	16 11	73 49	90 62	20 39	41 43	63 88	796 943	728 957	_	0 0	1 2	1 6	10
Minnesota Missouri	_	0	514	12	279	_	66	87	1,043	1,264	2	1	17	24	24
Nebraska§	3 1	9 2	28 9	145 34	173 37	23	195 28	269 57	2,354 578	4,143 498	_	0	5 2	23 7	14 3
North Dakota South Dakota	_	0 1	16 6	5 20	7 33	1	2 6	7 15	24 108	47 144	_	0 0	2 0	1	1
S. Atlantic	19	53	106	984	894	369	1,539	3,209	23,532	34,993	9	11	34	263	248
Delaware District of Columbia	1	1 1	4 7	13 34	10 24	22 20	27 38	44 63	565 936	612 766	_	0 0	3 2	5 3	1
Florida Georgia	15	24 11	44 27	472 181	367 215	_	440 339	551 2,068	1,564 3,895	9,688 6,651	4 1	3 2	8 7	80 55	80 62
Maryland§	2	4	12	88	58	119	130	221	2,452	2,978	1	2	5	45	31
North Carolina South Carolina [§]	1	0 1	0 8	29	43	41 97	328 179	676 1,026	6,468 4,817	7,354 4,061	3	1 1	9 4	36 24	15 20
Virginia [§] West Virginia	_	9 0	28 21	155 12	167 10	60 10	125 17	238 44	2,530 305	2,542 341	_	1 0	6 6	7 8	28 10
E.S. Central	1	9	34	168	149	283	541	879	9,687	12,647	_	2	9	52	57
Alabama [§] Kentucky	1 N	3 0	22 0	87 N	78 N	52	161 51	271 268	996 1,159	4,682 1,379	_	0 0	3 1	11 2	12 4
Mississippi Tennessee [§]	N	0 5	0 12	N 81	N 71	58 173	157 195	434 240	3,389 4,143	2,724 3,862	_	0 1	1 6	4 35	5 36
W.S. Central	8	7	53	121	95	65	944	1,490	18,446	20,379	1	2	30	50	43
Arkansas [§] Louisiana	2	3 1	13 6	52 22	30 36	65	80 210	142 366	1,655 3,958	1,886 4,244	_	0 0	2 3	3 4	4 10
Oklahoma	6	2	40	47	29	—	93	236	2,026	1,807	1	1	27	40	27
Texas [§] Mountain	N 11	0 30	0 67	N 521	N 572		558 281	938 454	10,807 4,177	12,442 5,932	4	0 4	2 11	3 133	2 109
Arizona	2 7	3	11	71	59	5	103	220	1,343	2,036	_	2	6	57	41
Colorado Idaho [§]	1	9 3	26 12	178 41	188 60	54	67 2	93 20	972 84	1,520 83	2	1 0	4 1	29 4	32 3
Montana [§] Nevada [§]	_	2 2	11 9	31 44	27 42	1	3 48	20 135	43 808	59 1,076	_	0	0 2	6	6
New Mexico [§]	1	1 6	6	37	24		30	64	603	724 373	1	0	4	16	17
Utah Wyoming [§]	_	1	27 4	107 12	165 7	11 1	16 2	28 5	297 27	61	1	0	3 1	20 1	10
Pacific Alaska	23 3	57 1	558 17	1,138 24	1,093 18	346 5	767 10	935 27	15,547 174	17,348 228	—	2 0	16 2	46 5	42 4
California	10	43	93	791	900	272	638	804	13,130	14,318	_	0	10	_	10
Hawaii Oregon§	1	1 8	4 14	26 154	24 151	_	14 26	26 46	275 440	433 593	_	0 1	2 6	2 39	9 19
Washington	9	0	449	143	_	69	73	142	1,528	1,776	—	0	5	—	_
American Samoa C.N.M.I.	U U	0	0	U U	U U	U U	0	4	U U	U U	U U	0	0	U U	U U
Guam Puerto Rico	1	0 5	0 19	86	 55	_	2 6	6 16	140	37 132	_	0 0	1 2	-	1
U.S. Virgin Islands	Ů	0	0	Ŭ	Ű	U	Ő	3	Ű	Ű	U	0	0	Ů	Ů

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

¹ Incidence data for reporting years 2006 and 2007 are provisional.
 ¹ Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
 ⁹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(22nd Week)*			Hepatit	tis (viral, a	cute), by t	ypet									
		Prev					Prev	B					egionellos vious	sis	
_	Current	52 w	eeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	<u>52 v</u>	veeks	Cum	Cum
Reporting area United States	27	Med 55	Max 177	2007	2006	47	Med 80	Max 392	2007 1,521	2006	week 15	Med 53	Max 114	2007 534	2006 599
New England	27	55 2	6	1,006 26	1,584 126	47	2	392 5	1,521 30	1,729 62		3	114	534 24	599 32
Connecticut	1	1	3	8	14	1	0	5	15	24	—	0	9	4	5
Maine [§] Massachusetts	_	0 1	2 4	8	5 81	_	0 0	2 1	2 2	10 16	_	0 1	2 11	13	3 20
New Hampshire Rhode Island§	—	0 0	2 2	6 3	17 3	—	0 0	2 4	5 5	7 4	—	0 0	2 6	6	3
Vermont [§]	_	0	1	1	6	_	0	1	1	1	_	0	2	1	1
Mid. Atlantic	3	7	20	131	154	—	10	21	177	230	2	15	55	133	170
New Jersey New York (Upstate)	_	2 1	5 11	21 31	52 32	_	2 1	6 13	30 35	77 28	_	2 6	10 30	12 44	26 54
New York City Pennsylvania	3	2 1	10 4	50 29	45 25	_	2 3	6 7	39 73	50 75	2	3 5	24 19	20 57	25 65
E.N. Central	4	6	17	94	131	2	9	23	174	200	4	10	31	103	115
Illinois Indiana	—	1	7 7	18 5	31 10	1	2	5 21	39 15	70 14	1	1	13 6	1 7	24 5
Michigan	1	2	8	34	43	_	2	8	48	62	_	3	10	39	22
Ohio Wisconsin	3	1 0	4 4	30 7	33 14	1	3 0	10 3	66 6	49 5	3	3 0	19 3	52 4	49 15
W.N. Central	_	2	17	60	62	2	2	15	53	57	_	1	16	18	19
lowa Kansas	_	0 0	4 1	13 2	4 19	1	0 0	3 2	10 5	9 6	_	0 0	3 3	2 1	2 1
Minnesota	_	0	17	33	3	_	0	13	4	6	—	0	11	4	_
Missouri Nebraska [§]	_	0 0	2 2	6 4	20 9	1	1 0	5 3	28 4	32 3	_	0 0	2 1	9 1	9 5
North Dakota South Dakota	_	0 0	3 2	2	7	_	0 0	1 1	2	1	_	0 0	1 1	1	2
S. Atlantic	10	9	27	186	, 205	12	21	56	409	501	5	8	25	129	133
Delaware		0	1	1	8		0	3	6	21		0	2	1	2
District of Columbia Florida	3	0 3	5 13	14 60	2 75	5	0 7	2 14	1 146	4 180	_	0 2	5 9	1 57	5 62
Georgia Maryland [§]	1	1	4 6	28 28	20 27	1	3 2	10 7	45 36	81 72	1	1 2	3 8	12 25	7 22
North Carolina	_	0	11	7	40	_	0	16	56	73	2	0	5	15	14
South Carolina [§] Virginia [§]	5	0 1	3 5	4 42	10 22	_	2 2	5 7	30 64	30 15	1 1	0 1	2 4	6 9	3 17
West Virginia	—	0	3	2	1	5	0	23	25	25		0	4	3	1
E.S. Central Alabama [§]	_	2 0	7 2	33 7	53 3	1	6 2	20 10	105 40	144 38	1	2 0	9 2	30 3	32 5
Kentucky Mississippi	—	0 0	2 4	5 6	23 4	1	1 0	3 8	8 9	34 17	1	1 0	6 2	14	8 1
Tennessee§	_	1	5	15	23	_	3	7	48	55	_	1	7	13	18
W.S. Central	_	6	19	63	138	18	18	159	273	280	_	1	15	26	18
Arkansas [§] Louisiana	_	0 0	2 4	4 8	31 8	_	1 1	7 6	7 17	28 21	_	0 0	1 2	1 1	1 6
Oklahoma Texas [§]	_	0 5	3 15	3 48	3 96	7 11	1 15	41 108	20 229	2 229	_	0 1	6 12	 24	1 10
Mountain	3	5	17	133	131	2	3	9	93	54	_	2	8	32	40
Arizona	2	4	14 3	108 12	72 21	1	0	5 2	40 16	15	—	0 0	4	10 6	14
Colorado Idaho [§]	1	0	1	2	6		0	2	4	6	_	0	2 3	2	5 5 2
Montana [§] Nevada [§]	_	0	3 2	2 6	5 7	_	0 1	0 5	19	16	_	0 0	1 2	1 3	2 4
New Mexico§	_	0	2	1	9	_	0	2	4	8	—	0	2	2	1
Utah Wyoming [§]	_	0 0	1 1	2	10 1	1	0 0	4 1	10	9	_	0 0	2 1	6 2	9
Pacific	6	14	92	280	584	9	10	106	207	201	3	1	11	39	40
Alaska California	4	0 12	1 40	2 251	1 555	9	0 8	3 31	3 156	1 164	3	0 1	1 11	31	40
Hawaii Oregon§	1	0 1	2 3	2 14	6 22	_	0 2	1 5	 29	5 31	_	0 0	0 1	1	_
Washington	1	0	52	11		_	0	74	19		_	0	2	7	_
American Samoa	U U	0	0	U U	U U	U	0	0	U U	U U	U	0	0	U	U
C.N.M.I. Guam	<u> </u>	0	0	_	_	U	0	0	—	_	U 	0	0	U	U
Puerto Rico U.S. Virgin Islands	U	1 0	10 0	25 U	22 U	1 U	1 0	9 0	21 U	21 U	U	0 0	2 0	3 U	1 U
	0	0		0	0	0	0	0	0		5	0	0	0	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. * Data for acute hepatitis C, viral are available in Table I. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			L	yme disea	ase			Ν	lalaria			Men		cal disea	ise, invasi ups	vet
Pepering area veck Med Max 2007 2008 veck Med Max 2007 2008 veck Med Max 7 19 84 475 50 New England 3 37 381 154 423 - 1 10 12 30 - 1 3 20 2 Mainsé - 1 38 18 283 - 0 3 1 - 0 3 1 - 0 3 1 - 0 3 1 - 0 3 - 0 3 1 - 0 3 - 0 3 - 0 3 3 - 0 3 1 - 0 1 1 0 0 - 1 1 0 0 - 1 1 0 0 0 1 1 0 0 0 1 <th></th> <th>0</th> <th></th> <th></th> <th>0</th> <th>0</th> <th>0</th> <th></th> <th></th> <th>0</th> <th></th> <th>0</th> <th></th> <th></th> <th>0</th> <th>0</th>		0			0	0	0			0		0			0	0
New Forly 3 37 381 164 428 - 1 10 12 30 - 1 3 20 20 Maine ² - 1 38 18 35 - 0 1 3 2 - 0 3 3 Maine ² - 0 3 1 - 0 1 - 0 3 3 3 Mide Band ² - 0 64 17 - 0 1 - 0 1 - 0 1 - 0 1 1 1 12 12 1 0 12 20 13 3	Reporting area															2006
$\begin{array}{c} \mbox{Concellul} & - & 10 & 227 & 62 & 73 & - & 0 & 3 & - & 1 & - & 0 & 2 & 4 \\ \mbox{Main}^{0} & - & 1 & 30 & 13 & 2 & - & 0 & 3 & 10 & 1 \\ \mbox{Mer} + \mbox{Mapshire} & - & 1 & 35 & 170 & 61 & 71 & - & 0 & 0 & - & 1 & - & - & - & 0 & 1 & 1 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 1 & 15 & 11 & 10 & - & 0 & 0 & - & 1 & - & - & 0 & 1 & 1 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 1 & 15 & 11 & 10 & - & 0 & 0 & - & 1 & - & 0 & 0 & - & 1 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 26 & 152 & 152 & 553 & - & 1 & 7 & - & 3 & 3 & - & 0 & 0 & 2 & 1 & 1 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 26 & 152 & 152 & 553 & - & 1 & 7 & - & 3 & 3 & - & 0 & 0 & 2 & 1 & 1 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 26 & 152 & 162 & 553 & - & 1 & 7 & - & 3 & 9 & 941 & 9 & - & 1 & 2 & 1 & 0 & 5 & 24 & 2 & - \\ \mbox{Mer} + \mbox{Mapshire} & - & 1 & 16 & 4 & 17 & - & 1 & 6 & 10 & 22 & - & 0 & 3 & 13 & 12 & - \\ \mbox{Mar} + \mbox{Mapshire} & - & 1 & 16 & 4 & 17 & - & 1 & 6 & 10 & 22 & - & 0 & 3 & 13 & 13 & - & 0 & 2 & 2 & 1 & - & 0 & 1 & 4 & - & 1 & 1 & - & 0 & 1 & 14 & - & 1 & 16 & 14 & 17 & - & 1 & 6 & 10 & 22 & - & 0 & 3 & 13 & 12 & - & 0 & 1 & 14 & - & 1 & 16 & 14 & 17 & - & 0 & 1 & 2 & - & 0 & 4 & 14 & - & 1 & 16 & 14 & - & 0 & 1 & 2 & - & 0 & 4 & 14 & - & 0 & 1 & 14 & - & 0 & 1 & 3 & 113 & - & 0 & 0 & 2 & - & 0 & 0 & - & 0 & 2 & - & 0 & 1 & - & 0 & 0 & 2 & - & 0 & 1 & - & 0 & 0 & 2 & - & 0 & 1 & - & 0 & 0 & 2 & - & 0 & 1 & - & 0 & 0 & 2 & - & 0 & 0 & - & 0 & 0 & - & 0 & 2 & 0 & 0 & - & 0 & 0 & 0 & - & 0 & 0 & 0$	United States	44	236	1,149	2,333	2,842	9	24	80	314	483	7	19	84	475	591
												_				25
New Hampshire 3 5 70 61 71 0 3 1 0 1 1 0 1 1 1												_				6 2
Rhode Bialand ² - 0 33 - 1 - 0 1 - 0 1 - 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 <th1< th=""> 1 1</th1<>																15 1
Nick Altantic 12 127 560 1,111 1,532 5 18 68 116 1 2 8 57 1 New Vork (Upstate) 46 426 309 438 1 7 18 9 1 2 15 7 PennsyNamia 12 40 223 694 516 1 4 9 12 1 0 5 24 3 PennsyNamia 12 40 223 694 516 1 4 9 12 1 0 5 24 3 1 1 1 5 24 3	Rhode Island [§]	_	0	93		1	_	0	1	—	—	—	0	1	1	_
$\begin{split} & \text{New Jork (Dipathe)} & - & 46 & 426 & 309 & 426 & - & 1 & 7 & - & 35 & - & 0 & 2 & 1 & 2 & 1 & 1 & 4 & 12 & 5 & 1 & 12 & 15 & 12 & 12 & 12 &$																1
New York Chip	New Jersey		26	192	102	553		1	7	_	35		0	2	1	93 11
Pennsyvania 12 40 223 694 516 - 1 4 9 12 1 0 5 24 25 Illinoia - 1 16 4 17 - 1 6 10 37 57 - 3 8 63 2 Illinoia - 1 16 4 17 - 1 6 10 3 13 10 Michigan - 1 15 8 4 - 0 2 7 8 - 0 3 13 10 Wisconsin - 4 154 64 87 - 1 2 9 21 1 1 1 1 1 5 31 3 1 7 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1																18 34
$\begin{array}{ $		12					_					1				30
Indiana 1 0 3 3 2 1 0 2 2 6 - 0 4 14 14 Michigan - 1 5 8 4 - 0 2 7 8 - 0 3 13 12 Ohio - 0 3 15 - 0 2 11 14 - 1 3 17 Wisconsin - 4 154 10 300 - 0 3 7 6 - 0 2 6 7 Karasan - 0 2 6 3 - 0 1 2 1 1 4 - 0 3 7 7 Karasan - 0 2 6 3 - 0 1 2 1 1 4 - 0 3 7 7 Karasan - 0 2 8 6 3 - 0 1 2 1 1 4 - 0 3 7 7 Karasan - 0 2 8 6 3 - 0 1 2 1 1 4 - 0 3 3 7 Karasan - 0 2 8 4 6 5 - 0 1 2 1 1 4 - 0 3 3 7 Karasan - 0 2 8 4 6 5 - 0 1 2 1 1 4 - 0 3 3 7 Karasan - 0 2 8 4 6 5 - 0 1 2 1 1 4 - 0 3 3 7 Nebraska ¹ - 0 3 2 - 4 - 0 1 2 2 1 - 0 1 3 2 Nebraska ¹ - 0 7 0 1 2 1 - 1 0 1 3 2 South Dakota - 0 7 0 1 1 - 1 - 0 3 3 1 1 7 Delaware - 2 9 28 205 156 - 0 1 2 3 - 0 1 1 1 0 1 2 Delaware - 2 9 28 205 156 - 0 1 2 3 - 0 1 1 0 1 1 0 Delaware - 0 7 1 3 7 - 0 2 3 0 1 1 - 1 0 1 1 0 Delaware - 0 7 2 3 1 0 1 1 0 1 2 Delaware - 0 7 2 3 0 0 1 2 - 1 0 1 1 0 1 1 0 Delaware - 0 7 2 3 0 0 1 2 - 0 1 0 1 0 1 0 Delaware - 0 7 2 3 0 0 1 2 - 0 1 0 1 0 1 0 Delaware - 0 7 2 3 0 0 1 0 1 0 1 0 Delaware - 0 7 2 3 0 0 1 0 1 0 1 0 Delaware - 0 7 2 3 0 Morthakota - 0 2 7 7 Morthakota - 0 2 2 5 3 1 0 2 3 4 - 0 2 2 5 Morthakota - 0 3 2 1 - 0 2 3 4 - 0 2 2 5 Morthakota - 0 3 2 1 - 0 2 2 0 2 2 1 1 - 0 2 4 1 Morthakota - 0 3 2 1 - 0 2 2 0 2 2 1 1 - 0 2 4 1 Morthakota - 0 3 2 1 - 0 2 2 0 2 2 0 2 2 0 2 2 0 2 2												_				88 25
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Indiana		0	3	3	2		0	2	2	6		0	4	14	11
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_					_									15 25
$ \begin{array}{c cva}{llllllllllllllllllllllllllllllllllll$		—					—					—	0	2		12
$\begin{array}{cccccccccccccccccccccccccccccccccccc$							_									35 9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Kansas	_	0	2	6	3		0	2	1	—	_	0	1	1	1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$							_									8 11
South Dakota - 0 1 - - 0 1 1 1 1 0 1 2 2 S. Atlantic 21 45 134 889 425 7 5 14 81 123 3 3 11 70 5 Delender O Columbia - 0 7 13 7 - 0 2 3 3 11 1 1 Deterror O Columbia - 0 7 13 7 - 0 2 3 3 3 11 7 0 1 1 1 1 1 0 1	Nebraska§		0	2	_			0	1	2	1	_	0	1	2	5
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							_									1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							7									97
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		_														3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$									4							38
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Maryland§	7	23	106	491	226	_	1	4	20	22		0	2	15	10 6
$\begin{array}{cccccccccccccccccccccccccccccccccccc$																15 11
E.S. Central - 1 4 11 2 - 0 3 14 9 - 1 4 28 2 Alabama ⁶ - 0 3 2 1 - 0 2 3 4 - 0 2 6 Mississippi - 0 1 - - 0 1 1 2 - 0 2 5 Mississippi - 0 1 - - 0 1 1 2 - 0 2 11 W.S. Central - 1 6 18 5 - 1 7 13 29 - 1 13 42 5 Louisiana - 0 0 - - - 0 3 11 2 - 0 4 11 2 Louisiana - 0 1 - - 0 3 11 1 5 41 3 3 11 1	Virginia [§]		8	36	151	15	—	1	4	14				2	7	11
Alabama [§] - 0 3 2 1 - 0 2 3 4 - 0 2 6 Kentucky - 0 2 - - - 0 1 3 1 - 0 2 5 Mississippi - 0 3 9 1 - 0 2 7 2 - 0 2 11 W.S. Central - 1 6 18 5 - 1 7 13 29 - 1 13 1 - 0 2 5 Louisiana - 0 1 2 - 0 2 - 1 1 0 2 5 - Louisiana - 0 1 2 - - 0 2 2 4 11 2 2 - 0 3 1 1 1 2 3 1 1 2 1 1 1 2 1 1<	, i i i i i i i i i i i i i i i i i i i						_									3 21
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Alabama§	_	0	3			_	0	2	3	4	_	0	2	6	4
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$																5 3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		—			9	1	_		2			—				9
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_					_					_				57 6
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Louisiana		0	1	2	_	—	0	2	11	1	—	0	4	11	26
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_					_					_				8 17
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mountain			3	8		1			22	24	1				36
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_		1 0	_						7 8	_				10 13
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Idaho§	_	0	2	2	_	_	0	1	_	_	1	0	1	3	13 1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Nevada§	_				_					_			-		2 3
Wyoming [§] - 0 1 - - - 0 0 - - - 0 2 1 Pacific 3 2 16 46 21 - 3 45 48 74 1 4 48 123 13 Alaska - 0 1 2 - - 0 4 2 8 - 0 1 1 4 48 123 13 California 2 2 8 43 21 - 2 6 33 58 - 3 10 90 11 Hawaii N 0 0 N N - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 2 - 0 1 <						1	_									1 4
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					—	_	—				_	—				2
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							—									139
Oregon [§] 1 0 1 1 - - 0 3 8 6 1 0 3 16 2 Washington - 0 8 - - - 0 43 3 - - 0 43 14 - American Samoa U 0 0 U U 0 0 U U 0 0 - <td>California</td> <td>2</td> <td>2</td> <td>8</td> <td>43</td> <td>21</td> <td>_</td> <td>2</td> <td></td> <td>33</td> <td>58</td> <td></td> <td>3</td> <td></td> <td>90</td> <td>2 110</td>	California	2	2	8	43	21	_	2		33	58		3		90	2 110
Washington - 0 8 - - 0 43 3 - - 0 43 14 - American Samoa U 0 0 U U 0 0 U U 0 0 - - - 0 43 14 - American Samoa U 0 0 U U 0 0 - - - 0 0 - - - 0 0 - - - - 0 0 - - - 0 0 - - - - 0 0 - - - - - - 0 0 - - - - - - 0 0 - - - - - - - - - - - - - 0 0 - - -				-			_									4 23
C.N.M.I. U U U U U U U U U U U		_			_	_	_									
Guam — 0 0 — — — 0 0 — — — 0 0 — —															—	_
Puerto Rico N 0 0 N N - 0 1 1 0 1 5	Guam	_	0	0		_		0	0	_			0	0	_	_
															5	_4

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(22nd Week)*			D				D. I.								
		Pres	Pertussi: /ious	S				ies, anin vious	nal		RC	<u> </u>	untain sp vious	otted feve	er
	Current	52 w	eeks	Cum	Cum	Current	52 v	veeks	Cum	Cum	Current	52 v	veeks	Cum	Cum
Reporting area United States	week 42	Med 255	Max 1,386	2007 2,950	2006 5,887	week 47	Med 96	Max 168	2007 1,684	2006 2,131	week 25	Med 24	Max 157	2007 314	2006 476
New England	42 1	36	77	456	950	4	11	25	1,004	2,131		0	9		5
Connecticut Maine [†]	1	2	10 15	18 33	27 23	1	4	14 8	67 31	54 34	N	0 0	0	N	N
Massachusetts	_	28	45	369	692	_	0	7		92		0	1		4
New Hampshire Rhode Island [†]	_	2 0	9 31	20	117 22	_2	1 0	4 3	16 16	8 9	_	0 0	1 9	_	1
Vermont [†]	_	1	9	16	69	_	2	10	66	29		0	0		_
Mid. Atlantic New Jersey	1	32 3	155 16	425 46	708 140	1	13 0	38 0	303	167	1	1 0	7 4	19	19 9
New York (Upstate) New York City	_	18 1	146 6	255	256 35	_	1	5	24	4	_	0 0	2 3	6	1 4
Pennsylvania	1	9	20	124	277	1	12	37	279	163	1	0	3	13	5
E.N. Central Illinois	10	41 9	80 23	603 62	824 214	5	2 0	18 7	37 3	32 7	_	1 0	9 4	7 1	21 13
Indiana Michigan	2	2 10	44 39	13 116	80 152	_1	0	2 5	5 8	2 17	_	0	1 1	1 1	1
Ohio	8	14	56	340	273	4	0	12	21	6	_	0	4	4	6
Wisconsin W.N. Central	4	3 17	17 151	72 179	105 606	5	0 6	0 19	 90	102	3	0 4	0 13	 58	1 38
Iowa	_	4	16	52	156	—	1	7	10	13	_	0	1	_	1
Kansas Minnesota	2	3 0	14 119	66	129 75	4	2 0	6 6	54 6	33 12	1	0	1 2	1	1
Missouri Nebraska†	1 1	3 1	10 4	35 8	169 61	_	1 0	6 0	8	9	1 1	3 0	12 5	54 3	34 2
North Dakota South Dakota	_	0 0	18 4	4 14	4 12	1	0 0	7 3	7 5	13 22	_	0 0	0 0	_	_
S. Atlantic	6	19	163	389	439	25	40	63	839	993	21	12	67	171	312
Delaware District of Columbia	_	0 0	1 2	3 2	2 3	_	0 0	0 0	_	_	_	0 0	3 1	4 1	8
Florida	3	4 1	18 7	103 6	90 33	_	0 5	24 9	55 81	176 103	1	0 0	4 5	7 5	7 12
Georgia Maryland [†]	2	2	7	50	73	_	6	12	116	185	_	1	7	16	12
North Carolina South Carolina [†]	1	1 3	112 11	145 36	77 64	9	11 3	21 11	206 46	165 56	19	6 0	61 5	109 6	254 5
Virginia† West Virginia	_	2 0	17 19	37 7	86 11	16	12 1	31 8	300 35	265 43	1	2 0	12 2	22 1	13 1
E.S. Central	_	6	24	77	120	_	4	11	60	105	_	5	27	54	63
Alabama [†] Kentucky	_	1 0	17 5	23 2	25 22	_	0 0	8 4	8	33 7	_	1 0	9 1	12 1	16
Mississippi Tennessee [†]	_	0 3	9 9	9 43	17 56	_	0 2	0 8	 52	4 61	_	0 4	1 22	 41	47
W.S. Central	4	17	153	185	276	3	15	35	33	362	_	1	114	4	9
Arkansas† Louisiana	4	2 0	17 2	42 6	30 16	_	0 0	5 1	10	15 2	_	0 0	53 1	_	6
Oklahoma Texas [†]	_	0 14	9 134	1 136	3 227	3	0 14	7 34	23	24 321	—	0 0	55 6	4	1
Mountain	9	29	63	514	1,390	3	2	34 28	41	63	_	0	4	4	2 8
Arizona Colorado	- 6	6	16	127 141	312	2	2 0	10 0	36	50	—	0 0	2	_	2 1
Idaho [†]		1	18 7	20	481 31	_	0	24	_	_	_	0	3	1	_
Montana [†] Nevada [†]	_	1 0	8 9	24 3	49 37	_	0 0	2 1	_	6	_	0 0	2 0	_	_
New Mexico [†] Utah	3	2 9	8 48	17 170	39 410	1	0 0	1	1 3	5 1	_	0 0	1 0	_	3
Wyoming [†]	—	1	8	12	31	_	0	2	1	1	—	0	1	—	2
Pacific Alaska	7 2	24 1	547 8	122 13	574 32	1	4 0	13 6	85 33	81 13	N	0 0	1 0	N	1 N
California Hawaii	_	21 0	225 5	10	421 54	1 N	3	12 0	52 N	66 N	N	0	0	N	N
Oregon [†]	_	1	11	42	67	—	Ō	4	_	2		0	1	_	1
Washington American Samoa	5 U	0 0	377 0	57 U	— U	 U	0 0	0 0	— U	 U	N U	0 0	0 0	N U	N U
C.N.M.I.	U	_	_	U	Ŭ	U	_	_	Ŭ	U	U	_	_	Ŭ	U
Guam Puerto Rico		1 0	7 1		13		0 1	0 4	19	49	N N	0	0	N N	N N
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(22nd Week)*	-									_					
		-	almonello	osis		Shiga t		-	E. coli (ST	EC)†			Shigellos	is	
	Current		rious reeks	Cum	Cum	Current	52 w	vious veeks	Cum	Cum	Current	52 v	vious veeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	344	837	1,877	11,409	12,742	23	73	315	872	843	173	280	874	4,635	4,219
New England Connecticut	2	36 0	129 115	586 115	1,226 503	_	3 0	23 9	51 9	122 75	_	4 0	21 12	77 12	200 67
Maine [§] Massachusetts	1	2 23	14 87	38 335	38 585	_	1 2	8 13	12 21	4 36	_	0 3	5 18	8 50	2 121
New Hampshire	_	3	15	38	56	_	0	3	5	4	_	0	2	3	3
Rhode Island [§] Vermont [§]	1	2 1	15 6	41 19	31 13	_	0 0	2 4	1 3	1 2	_	0 0	3 2	3 1	5 2
Mid. Atlantic	22	96	189	1,471	1,495	_	8	63	86	106	2	13	47	179	351
New Jersey New York (Upstate)	_	20 27	50 112	54 452	301 313	_	1 3	20 15	1 40	31 33	_	2 3	34 42	13 40	128 85
New York City Pennsylvania	2 20	23 32	45 66	401 564	411 470	_	0 3	4 47	8 37	17 25	2	5 1	12 6	96 30	101 37
E.N. Central	50	93	203	1,485	1,831	2	9	63	103	129	14	25	75	291	427
Illinois Indiana	 19	29 15	65 55	290 214	525 200	_	1 1	8 8	12 11	15 14	_	9 2	53 17	35 24	143 54
Michigan	1	18	35	283	333	_	1	6	20	26		2	5	15	79
Ohio Wisconsin	30	23 17	56 32	426 272	446 327	_2	3 2	18 41	44 16	37 37	14	4 4	23 14	159 58	68 83
W.N. Central Iowa	38	50 8	109 26	931 139	799 137	3	11 2	45 38	128 20	131 25	12	44 2	156 14	873 23	517 18
Kansas Minnesota	11 12	7 12	20 60	155 234	118 188	1	03	4 26	13 55	5 39	3	1 5	10 24	13 101	36 31
Missouri	9	15	35	264	228	1	2	13	23	42	9	14	72	706	352
Nebraska [§] North Dakota	2 4	3 0	11 23	61 15	74 6	1	1 0	11 12	16	13 2	_	1 0	14 127	7 4	34 3
South Dakota	_	3	11	63	48	—	0	5	1	5	—	6	24	19	43
S. Atlantic Delaware	134 1	225 3	401 10	3,122 35	2,916 30	11	13 0	32 3	203 6	134 1	89	76 0	150 2	1,737 4	986
District of Columbia Florida	1 65	1 93	4 176	16 1,362	23 1,292	1	0	1 8	1 57	 30		0 39	5 76	4 1,076	3 443
Georgia	3	30	73	456	428	_	2	7	20	23	12	26	62	543	351
Maryland§ North Carolina	14 30	14 29	32 130	223 474	140 462	1 8	3 2	9 11	35 33	9 29	3	2 1	10 14	26 28	19 82
South Carolina [§] Virginia [§]	14 6	18 20	47 58	253 265	258 250	1	0 3	3 11	5 45	3 39	2	0 2	4 9	27 28	65 23
West Virginia	_	1	31	38	33	_	0	5	43		_	0	2	1	
E.S. Central Alabama [§]	6 1	51 11	139 70	718 206	724 241	1	4 0	21 5	39 8	58 6	15 11	13 6	89 66	357 156	275 71
Kentucky	5	9	23	160	127	1	1	12	13	13	4	2	15	45	131
Mississippi Tennessee [§]	_	12 17	101 32	118 234	151 205	_	0 2	3 9	1 17	1 38	_	2 3	76 14	86 70	31 42
W.S. Central	23	87	189	486	1,194	1	4	52	51	42	27	39	246	431	579
Arkansas [§] Louisiana	9	13 18	45 48	146 120	282 256	_	1 0	7 0	11	9	_2	2 5	10 25	43 68	31 66
Oklahoma Texas [§]	14	10 37	103 107	134 86	86 570	1	0 2	17 48	11 29	4 29	1 24	2 30	60 174	29 291	32 450
Mountain	18	50	88	889	914	1	9	34	110	94	10	22	84	278	333
Arizona Colorado	7 9	17 11	44 30	314 242	260 276	_	2 1	9 8	43 19	25 24	9 1	10 3	37 15	140 46	174 48
Idaho§	—	3	9	41	50	—	1	8	7	14	_	0	3	4	6
Montana [§] Nevada [§]	_	2 5	10 20	34 69	49 59	1	0 0	0 5	9	11	_	0 1	13 20	12 13	2 41
New Mexico [§] Utah	2	4 4	15 14	71 95	78 116	_	1 2	5 14	14 18	8 10	_	2 1	15 4	38 8	39 20
Wyoming [§]	_	1	4	23	26	_	0	3		2	_	0	19	17	3
Pacific Alaska	51 1	105 1	890 5	1,721 33	1,643 33	4 N	4 0	164 0	101 N	27 N	4	33 0	256 2	412 6	551 4
California	37	90	260	1,310	1,358	2	0	8	58	N	4	28	84	330	467
Hawaii Oregon [§]	1	5 7	16 17	86 98	87 165	_	0 1	3 9	6 13	4 23	_	1 1	3 6	13 21	18 62
Washington	12	0	625	194 U	—	2 U	0	162	24 U	— U	— U	0	170	42	—
American Samoa C.N.M.I.	U U	0	0	U	U U	Ŭ	0	0	Ŭ	Ū	Ū	0	0	U U	U U
Guam Puerto Rico	2	0 15	0 66	259	133	<u>N</u>	0 0	0 0	N	N	1	0 0	0 6	12	9
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	U	0	0	U	Ű

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. * Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	Stre	ptococcal	disease,	invasive, g	roup A	Strept		neumonia Age <5 yea	<i>e</i> , invasive ars	disease [†]	
	Current	Prev	vious veeks	Cum	Cum	Current		ious	Cum	Cum	
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	
United States	47	85	251	2,336	2,858	16	28	104	686	690	
New England	—	6	29	169	240	—	2	11	56	85	
Connecticut Maine [§]	_	0 0	17 2	35 9	55 9	_	0 0	6 1	1	20	
Massachusetts	—	3	10	95	145	_	2	6	42	60	
New Hampshire Rhode Island [§]	_	0 0	5 12	19	20 4	_	0 0	2 3	6 5	5	
Vermont [§]	_	Ő	2	11	7	_	0	1	2	_	
Mid. Atlantic	3	15	41	422	539	_	3	20	54	97	
New Jersey New York (Upstate)	_	1 5	6 27	28 147	98 158	—	0 2	4 15	 54	38 50	
New York City	_	3	11	98	97	_	0	3		9	
Pennsylvania	3	6	11	149	186	Ν	0	0	N	Ν	
E.N. Central	11	15	29	414	607	_	5	14	100	174	
Illinois Indiana	5	4 2	10 12	81 62	186 66	_	1 0	6 10	9 10	48 22	
Michigan	1	4	10	108	126	_	1	4	41	43	
Ohio	5	4 1	14	144	158	_	1	7	35 5	33 28	
Wisconsin			6	19	71		0	2			
W.N. Central lowa	4	5 0	32 0	189	180	1	2 0	8 0	60	51	
Kansas	_	1	3	24	37	_	0	1	1	9	
Minnesota Missouri	4	0 2	29 6	90 49	78 33	1	1 0	6 2	41 13	26 10	
Nebraska§	_	0	3	13	19	_	0	2	4	4	
North Dakota	—	0	2	9	6	—	0	2	1	2	
South Dakota		0	2	4	7	_	0	0	_	—	
S. Atlantic Delaware	15	20 0	48 2	538 4	547 5	6	2 0	13 0	136	34	
District of Columbia		0	3	8	7		0	1		_	
Florida Georgia	4 2	6 5	16 11	131 107	127 144	1	0 0	5 5	32 42	_	
Maryland [§]	5	4	8	97	75	1	1	6	37	26	
North Carolina	2	0	26 7	56 50	67 41	3	0 0	0 3	 15	—	
South Carolina [§] Virginia [§]	2	1 2	11	50 72	67	3	0	3	8	_	
West Virginia	—	0	3	13	14	_	0	4	2	8	
E.S. Central	1	4	11	91	118		0	6	42	10	
Alabama [§] Kentucky	N 1	0 1	0 4	N 25	N 29	N	0 0	0 0	N	N	
Mississippi	Ň	0	0	N	N	_	0	2	2	10	
Tennessee§	—	3	7	66	89	—	0	6	40	—	
W.S. Central	7	6	80	147	206	1	4	39	110	104	
Arkansas [§] Louisiana	_	0 0	2 2	12 4	18 8	_	0 0	2 4	7 24	14 16	
Oklahoma	1	2	21	42	58		1	12	24	21	
Texas [§]	6	3	56	89	122	1	1	24	55	53	
Mountain Arizona	6 2	11 5	23 11	304 120	376 202	7 4	4 2	12 7	110 62	122 72	
Colorado	4	3	9	94	62	3	1	4	33	29	
Idaho [§] Montana [§]	N	0	1 0	6 N	6 N	N	0 0	1 0	2 N	1 N	
Nevada§		0	1	2	1		0	1	1		
New Mexico [§]	_	1	6	25	68	—	0	4	12	20	
Utah Wyoming [§]	_	1 0	7 1	54 3	35 2	_	0 0	0 0	_	_	
Pacific	_	3	9	62	45	1	0	4	18	13	
Alaska	_	0	2	15	N	1	0	2	16	_	
California Hawaii	N	0 2	0 9	N 47	N 45	N	0 0	0 2	N 2	N 13	
Oregon§	N	2	9	47 N	45 N	N	0	2	N	N	
Washington	N	0	0	Ν	Ν	Ν	0	0	Ν	Ν	
American Samoa	U	0	0	U	U	U	0	0	U	U	
C.N.M.I. Guam	U	0	0	U	U	U N	0	0	U N	U N	
Puerto Rico	_	0	0	_	_	N	0	0	N	Ν	
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting years 2006 and 2007 are provisional. Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717). § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

		Str			<i>oniae</i> , inva	sive diseas	/								
			All ages				-	<5 year	s		Sy			d second	ary
	Current	Previ 52 we		Cum	Cum	Current	Prev 52 w	ious eeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	19	44	254	1,177	1,313	4	8	35	212	197	55	183	310	3,376	3,760
New England	_	1	12	26	76	_	0	3	5	2	1	4	13	87	81
Connecticut Maine [§]	_	0 0	5 2	5	59 4	_	0 0	0 2	1	1	_	0 0	10 1	10 2	17 5
Massachusetts	_	0	0	_	—	_	0	0	_	_	1	3	7	55	45
New Hampshire Rhode Island [§]	_	0 0	0 4	10	5		0 0	0 1	2	_	_	0 0	2 5	10 9	5 7
Vermont§	—	0	2	11	8	—	0	1	2	1	_	0	1	1	2
Mid. Atlantic	1	3 0	9	75	79	_	0 0	5 0	17	10	13	24 3	44 8	635 57	489 74
New Jersey New York (Upstate)	_	1	0 5	 25	22	_	0	4	7	4	_	3	8 14	57 48	65
New York City Pennsylvania	1	0 2	0 6	 50	 57	_	0 0	0 2	 10	6	13	15 5	35 12	435 95	240 110
E.N. Central	12	10	40	299	296	1	1	7	36	47	3	15	32	280	371
Illinois	_	0	3	3	14	_	0	1	1	3	_	6	13	106	204
Indiana Michigan	6	2 0	31 1	74 1	69 14	1	0	5 0	7	13 2	_	1 2	5 10	18 46	34 35
Ohio	6	5	38	221	199	_	1	5	28	29	3	4	9	85	81
Wisconsin	N	0	0	N	N	_	0	0	_	_	_	1	4	25	17
W.N. Central Iowa	_	1 0	124 0	89	22		0 0	15 0	4	1	1	4 0	14 3	56 4	113 7
Kansas	—	0	10	48	—	_	0	2	2	—	_	0	3	8	11
Minnesota Missouri	_	0 1	123 5	34	22	_	0 0	15 1	_	1	_	1 2	5 8	21 21	25 67
Nebraska§	_	0	1 0	_2	_	_	0	0	_	_	_	0 0	2	1	2
North Dakota South Dakota	_	0	3	5	_	_	0 0	0 1	2	_	1	0	0 3	1	1
S. Atlantic	5	21	59	526	630	3	4	15	116	91	19	37	180	574	812
Delaware District of Columbia	_	0	1 2	4 5		_	0	1 0	1	2	2	0 2	3 11	5 65	12 48
Florida	5	11	29	307	320	2	2	8	68	60	_	11	24	68	301
Georgia Maryland [§]	_	6 0	16 1	176 1	226	1	1 0	10 0	40	29	2	4 5	153 15	33 118	103 138
North Carolina	_	0	0	—	_	_	0	0	_	_	12	5	23	152	117
South Carolina [§] Virginia [§]	N	0 0	0	N	N	_	0	0 0	_	_	3	1 4	10 17	46 84	34 57
West Virginia	—	1	17	33	67		0	1	7	—	—	0	2	3	2
E.S. Central Alabama [§]	N	2 0	9 0	74 N	98 N	_	0 0	3 0	16	16	10	15 5	29 17	304 95	241 102
Kentucky		0	2	16	23	_	0	1	2	3	1	1	7	33	32
Mississippi Tennessee§	_	0 2	0 8	 58	 75	_	0 0	0 3	 14	 13	1 8	2 6	9 13	48 128	25 82
W.S. Central	1	1	9	62	55		0	2	10	6	4	30	56	619	587
Arkansas§	_	0	3	1	5	_	0	0	_	2	4	1	7	47	33
Louisiana Oklahoma	1	1 0	3 8	22 39	50	_	0 0	1 2	2 8	_4	_	7 1	30 5	143 31	83 32
Texas§	_	0	0	_	—	_	0	0	_	—	_	21	31	398	439
Mountain	—	1	5	26	57	—	0	5	8	24	2	7	27	112	209
Arizona Colorado	_	0 0	0	_	_	_	0 0	0 0	_	_	2	2 1	16 5	31 12	81 36
Idaho [§] Montana [§]	Ν	0	0	N	N	_	0 0	0 0	—	_	_	0 0	1 1	1 1	2 1
Nevada§	_	0	3	15	14	_	0	2	5	_	_	2	12	36	59
New Mexico§ Utah	_	0 0	0 5	8	24	_	0	0 4	2	 16	_	1 0	7 2	27 3	26 4
Wyoming [§]	_	0	3	3	19	_	0	1	1	8	_	0	1	1	_
Pacific	_	0	0	—	—		0	0	—	—	2	38	57	709	857
Alaska California	N	0 0	0 0	N	N	_	0 0	0 0	_	_	2	0 34	2 54	5 646	5 751
Hawaii	_	0	0	_	—	_	0	0	_	—	_	0	1	2	11
Oregon [§] Washington	N N	0 0	0 0	N N	N N	_	0 0	0 0	_	_	_	0 2	6 11	8 48	8 82
American Samoa	U	0	0	U	U	U	0	1	U	U	U	0	0	U	U
C.N.M.I.	U N	0	0	U N	U	Ŭ	0	0	U	U	Ŭ	0	0	U	U
Guam Puerto Rico	N	0	0	N	N N	_	0	0	_	_	_	3	11	56	67
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Max * Incidence data for reporting years 2006 and 2007 are provisional. * Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720). * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(22nd week)*									t Nile viru	s disease	,t				
			ella (chicl	(enpox)				roinvasi	ve				neuroinv	asive§	
	Current		/ious	C	C	Current		/ious	C	C	Current		vious	C	C
Reporting area	Current week	5∠ w Med	veeks Max	Cum 2007	Cum 2006	week	Med	veeks Max	Cum 2007	Cum 2006	Current week	Med	veeks Max	Cum 2007	Cum 2006
United States	560	771	1,581	20,009	26,626		0	178		12	-	1	399		6
New England		24	209	314	2,480		0	3				0			0
Connecticut	2	24	209	1	2,480	_	0	3	_	_	_	0	2 1	_	_
Maine ¹	_	1	9	_	151	_	0	0	—	—	_	0	0	_	_
Massachusetts New Hampshire	2	0 6	95 17	127	865 202	_	0	1 0	_	_	_	0 0	1 0	_	_
Rhode Island ¹		0	0		202	_	0	0	_	_	_	Ő	0	_	_
Vermont [®]	—	9	66	186	348	—	0	0	—	—	—	0	0	—	—
Mid. Atlantic	89	105	195	2,490	2,754	_	0	11	_	_	_	0	4	_	_
New Jersey	N	0	0	N	N	—	0	2 5	—	—	—	0 0	1	—	_
New York (Upstate) New York City	N	0	0	N	N	_	0	5 4	_	_	_	0	1 2	_	_
Pennsylvania	89	105	195	2,490	2,754	_	0	2	—	—	_	0	1	_	_
E.N. Central	149	218	568	5,918	9,224	_	0	43	_	2	_	0	33	_	_
Illinois	_	2	11	71	71	—	0	23	_	1	_	0	23	—	_
Indiana Michigan	44	0 88	0 258	2,298	2,669	_	0 0	7 11	_	1	_	0 0	12 2	_	_
Ohio	105	118	449	2,979	5,791	_	0	11	_	_	_	0	3	_	_
Wisconsin	—	17	57	570	693	_	0	2	_	_	_	0	2	—	_
W.N. Central	44	32	136	1,129	1,134	—	0	36	—	—	—	0	79	—	1
lowa Kansas	N 14	0 8	0 52	N 418	N 220	_	0	3 3	_	_	_	0 0	4 3	_	1
Minnesota		0	0	410		_	0	6	_	_	_	Ő	7	_	_
Missouri	30	16	78	574	865	—	0	14	—	_	—	0	2	_	—
Nebraska ¹ North Dakota	N	0	0 60	N 84	N 18	_	0	9 5	_	_	_	0 0	38 28	_	_
South Dakota	_	1	15	53	31	_	0	7	_	_	_	ŏ	22	_	_
S. Atlantic	68	85	224	2,270	2,494	_	0	2	_		_	0	7	_	_
Delaware	_	1	6	໌ 13	41	_	0	0	_	—	_	0	0	_	_
District of Columbia Florida	6 24	0	8 89	14 680	18 N	_	0 0	0 1	_	_	_	0 0	1 0	_	_
Georgia	N	0	0	N	N	_	0	1	_	_	_	Ő	4	_	_
Maryland	N	0	0	N	N	—	0	2	—	—	—	0	2	—	—
North Carolina South Carolina ¹	6	0 17	0 72	588	717	_	0 0	1 1	_	_	_	0 0	0 0	_	_
Virginia ¹	_	18	176	331	811	_	Ő	Ö	_		_	Ő	2	_	_
West Virginia	32	25	50	644	907	_	0	1	_	_	_	0	0	—	_
E.S. Central	1	6	43	252	54	—	0	15	—	3	—	0	16	_	—
Alabama ¹ Kentucky	1 N	6 0	43 0	250 N	54 N	_	0	2 2	_	_	_	0 0	0 1	_	_
Mississippi	_	0	2	2	—	_	Ő	10	_	3	_	0	16	_	_
Tennessee ¹	N	0	0	N	N	_	0	4	_	_	_	0	2	—	_
W.S. Central	198	191	979	6,013	6,757	_	0	58	_	5	_	0	26	_	2
Arkansas ¹ Louisiana	1	9 1	105 11	179 46	437 168	_	0	4 13	_	_	_	0 0	2 9	_	1
Oklahoma	_	Ó	0			_	0	6	_	_	_	Ő	4	_	_
Texas ¹	197	170	873	5,788	6,152	—	0	38	—	5	—	0	16	—	1
Mountain	9	55	133	1,601	1,729	—	0	61	—	2	—	0	228	—	2
Arizona Colorado	7	0 22	0 62	619	894	—	0 0	9 10	—	2	—	0 0	15 51	—	1
Idaho ¹	Ň	0	02	N	094 N	_	0	30	_		_	0	157	_	1
Montana ¹	_	0	26	206	N	_	0	3	_	_	_	0	8	_	_
Nevada ¹ New Mexico ¹	_	0 5	1 39	1 238	8 285	_	0	9 1	_	_	_	0 0	16 1	_	_
Utah	2	17	73	524	513	_	0	8	_	_	_	Ő	17	_	_
Wyoming ¹	—	0	11	13	29	—	0	7	—	_	—	0	10	_	—
Pacific	_	0	9	22		_	0	15	—	—	_	0	51	_	1
Alaska California	_	0	9 0	22	N N	_	0 0	0 15	_	_	_	0 0	0 37	_	1
Hawaii	_	0	0	_		_	0	0	_	_	_	0	0	_	
Oregon ¹	N	0	0	N	Ν	_	0	2	_	_	_	0	14	_	_
Washington	N	0	0	N	N	_	0	0	_	_	_	0	2	_	_
American Samoa	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U
C.N.M.I. Guam	U	4	14	U	U 135	U	0	0	U	U	U	0	0	U	U
Puerto Rico	13	12	27	325	252	_	0	0	_	_	_	0	0	_	_
U.S. Virgin Islands	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. Incidence data for reporting years 2006 and 2007 are provisional. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I. Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phsi/infdis.htm.

569

TABLE III. Deaths in 122 U.S. cities,* week ending June 2, 2007 (22nd Week)


TABLE III. Deaths	in 122 U.S. cities,* week ending June 2, 2007 (All causes, by age (years)					(22nd W	/eek)	All causes, by age (years)							
	All				/		P&I [†]		All		1	, , ,			P&I [†]
Reporting Area	Ages	<u>></u> 65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total
New England	459	315	96	24	12	12	44	S. Atlantic	1,054	684	239	71	35	25	46
Boston, MA	132	79	32 6	11	3	7 1	11	Atlanta, GA	155	85	41	22 5	6	1	9
Bridgeport, CT Cambridge, MA	29 16	22 12	3	_	1	_	7 2	Baltimore, MD Charlotte, NC	118 106	77 70	28 23	5	6 1	2 5	3 6
Fall River, MA	18	13	5		_	_	2	Jacksonville, FL	160	114	23 35	2	8	1	6
Hartford, CT	47	34	7	3	2	1	2	Miami, FL	85	65	11	3	3	3	6
Lowell, MA	12	11	1	_	_		3	Norfolk, VA	33	22	6	1	_	4	_
Lynn, MA	12	11	1	_	_	_	2	Richmond, VA	48	24	18	2	3	1	6
New Bedford, MA	20	14	5	_	_	1	3	Savannah, GA	46	26	12	5	3	_	_
New Haven, CT	U	U	U	U	U	U	U	St. Petersburg, FL	49	29	12	6	1	1	1
Providence, RI	48	33	9	4	1	1	3	Tampa, FL	151	101	34	12	3	1	6
Somerville, MA	3	2	—	—	1	—	—	Washington, D.C.	77	51	15	4	1	6	1
Springfield, MA	29	19	8	1	1	_	2	Wilmington, DE	26	20	4	2	—	—	2
Waterbury, CT	25	17	6	2	_		_	E.S. Central	702	441	192	44	15	10	60
Worcester, MA	68	48	13	3	3	1	7	Birmingham, AL	158	111	32	9	3	3	11
Mid. Atlantic	1,723	1,199	356	114	31	20	92	Chattanooga, TN	60	43	12	4	1	_	2
Albany, NY	36	21	11	3	—	1	2	Knoxville, TN	94	57	30	6	_	1	10
Allentown, PA	16	11	5	_	_	_	1	Lexington, KY	47	27	13	4	3	_	2
Buffalo, NY	68	47	15	3	1	2	2	Memphis, TN	143	86	46	5	3	3	12
Camden, NJ	31	17	10	3	_	1	_	Mobile, AL	43	20	17	4	_	2	6
Elizabeth, NJ Erie, PA	14 30	7 25	5 4	2 1	_	_	2 2	Montgomery, AL Nashville, TN	37 120	26 71	6 36	3 9	1 4	1	5 12
Jersey City, NJ	20	25 16	3	1	_	_	1	, í							
New York City, NY	948	681	187	57	13	8	39	W.S. Central	1,219	779	281	86	37	36	72
Newark, NJ	53	24	16	9	2	1	4	Austin, TX	75	53	16	3	2	1	6
Paterson, NJ	23	13	3	5	1	1	2	Baton Rouge, LA	52	32	12	2	2	4	2
Philadelphia, PA	132	80	35	13	3	1	7	Corpus Christi, TX Dallas, TX	46	33	7	4	1	1 7	14
Pittsburgh, PA§	32	19	8	4	1	—	3	El Paso, TX	171 73	95 53	43 14	19 4	7 2		14
Reading, PA	34	24	8	1	1	_	3	Fort Worth, TX	117	78	32	4	2 1	2	8
Rochester, NY	135	102	21	2	6	4	10	Houston, TX	277	177	66	18	9	7	17
Schenectady, NY	15	12	3	_	_	_	1	Little Rock, AR	75	47	15	5	4	4	4
Scranton, PA	28 62	21 49	2 11	3 1	1 1	1	3 8	New Orleans, LA ¹	U	U	U	U	U	U	U
Syracuse, NY Trenton, NJ	17	49	4	4	_	_	0 1	San Antonio, TX	178	122	34	10	4	8	9
Utica, NY	12	8	2	1	1	_	_	Shreveport, LA	58	37	11	7	2	1	6
Yonkers, NY	17	13	3	1	_		1	Tulsa, OK	97	52	31	10	3	1	5
E.N. Central	1,721	1,145	380	125	37	34	115	Mountain	836	529	170	86	31	20	43
Akron, OH	[´] 54	36	15	3	_	_	2	Albuquerque, NM	88 30	56	18 1	11 4	1	2 1	4
Canton, OH	24	22	2	_	—	—	5	Boise, ID Colorado Springs, CO	30 64	23 43	12	4 5	2	2	2 1
Chicago, IL	310	168	87	37	11	7	23	Denver, CO	87	43 56	14	9	3	5	3
Cincinnati, OH	76	56	9	5	2	4	8	Las Vegas, NV	206	126	55	17	8	_	16
Cleveland, OH	165	120	36	4	3	2	7	Ogden, UT	23	12	6	2	2	1	1
Columbus, OH Dayton, OH	169 132	110 86	35 34	14 6	4 5	6 1	8 9	Phoenix, AZ	122	71	22	18	4	7	4
Detroit, MI	154	88	38	16	7	5	13	Pueblo, CO	18	10	5	3			
Evansville, IN	38	30	4	1	3	_	2	Salt Like City, UT	105	70	17	7	9	2	10
Fort Wayne, IN	71	54	11	4	_	2	3	Tucson, AZ	93	62	20	10	1	_	2
Gary, IN	8	3	5	—	—	_	—	Pacific	1,170	790	261	75	26	18	92
Grand Rapids, MI	61	40	18	3	_	_	7	Berkeley, CA	14	12	1	1		_	1
Indianapolis, IN	103	63	24	13	_	3	7	Fresno, CA	62	42	13	6	1		5
Lansing, MI	38 97	32 69	3	2 6	I	1	2 3	Glendale, CA	U 66	U 47	U 12	U 3	U 3	U 1	U 5
Milwaukee, WI Peoria, IL	35	27	21 5	2	_	1	3	Honolulu, HI Long Beach, CA	67	47	12	4	1	1	10
Rockford, IL	40	27	9	2	_	2	3	Los Angeles, CA	U U	43 U	U	Ŭ	Ů	ΰ	Ŭ
South Bend, IN	35	25	7	3	_		1	Pasadena, CA	28	24	1	2	_	1	4
Toledo, OH	67	49	14	4	_	_	6	Portland, OR	70	48	13	6	_	3	4
Youngstown, OH	44	40	3	—	1	—	3	Sacramento, CA	171	124	30	9	5	3	14
W.N. Central	419	280	98	19	10	12	33	San Diego, CA	134	84	29	12	6	3	13
Des Moines, IA	45	39	5	1			8	San Francisco, CA	125	77	31	11	3	3	10
Duluth, MN	19	10	6	1	1	1	_	San Jose, CA	131	93	28	8	1	1	12
Kansas City, KS	17	9	7	_	1	_	_	Santa Cruz, CA	32	24	7	1	3	2	2 4
Kansas City, MO	80	47	22	4	3	4	4	Seattle, WA Spokane, WA	105 70	62 45	30 23	8 1	3	2	4
Lincoln, NE	31	22	8	1			4	Tacoma, WA	70 95	45 65	23 25	3	2	_	0 2
Minneapolis, MN	53	33	12	3	2	3	5								
Omaha, NE	64	44	16	2	1	1	7	Total	9,303**	6,162	2,073	644	234	187	597
St. Louis, MO St. Paul, MN	14 52	3 40	6 9	2 1	2	1 2	2								
Wichita, KS	52 44	40 33	9 7	4	_		2								
		00	'	T			0	1							

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza.

¹Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. ** Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals June 2, 2007, with historical data



* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data TeamPatsy A. HallDeborah A. AdamsRosaline DharaWillie J. AndersonVernitta LoveLenee BlantonPearl C. Sharp

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2007-623-038/41030 Region IV ISSN: 0149-2195